Graduate Theses, Dissertations, and Problem Reports
2018

The Determination and Evaluation of Pyrolytic Products: A Focus
on Synthetic Cannabinoids
Stephen Raso

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Raso, Stephen, "The Determination and Evaluation of Pyrolytic Products: A Focus on Synthetic
Cannabinoids" (2018). Graduate Theses, Dissertations, and Problem Reports. 6481.
https://researchrepository.wvu.edu/etd/6481

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

The Determination and Evaluation of Pyrolytic Products:
A Focus on Synthetic Cannabinoids

Stephen Raso

Dissertation submitted to the
Eberly College of Arts and Sciences
at West Virginia University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in Chemistry

Suzanne Bell, Ph.D., Chair
Jonathan Boyd, Ph.D.
Harry Finklea, Ph.D.
Glen Jackson, Ph.D.
Patrick Callery, Ph.D.
C. Eugene Bennett Department of Chemistry

Morgantown, West Virginia
2018

Key Words: synthetic cannabinoids, pyrolysis, thermal degradation, gas chromatograph mass
spectrometry, liquid chromatography mass spectrometry
Copyright 2018 Stephen Raso

Abstract
The Determination and Evaluation of Pyrolytic Products: A Focus on
Synthetic Cannabinoids
Stephen Raso
Synthetic cannabinoids have become a ubiquitous challenge in forensic toxicology and
seized drug analysis. Acute toxic effects associated with these drugs include tachycardia,
seizures, depression, possible suicidal tendencies, and the onset of psychotic episodes. Synthetic
cannabinoids were initially synthesized for research purposes in understanding the receptorligand interactions at the CB1 and CB2 cannabinoid receptors. They are similar to Δ9tetrahydrocannabinol (THC) and also act as agonists at the cannabinoid receptors. Originally it
was hoped that this class of drug would be useful for pain relief, but instead this class of
compounds has become widely abused, typically via smoking or heated vapor inhalation. The
mode of ingestion is important in this context as heating creates many new potentially toxic
agents, some of which may interact with the cannabinoid receptors as well.
The objectives of this research are to determine pyrolytic products produced from the
smoking process of selected representative synthetic cannabinoids and evaluate their presence in
true case samples to establish the necessity for inclusion in toxicological assessment. This is a
timely project given that current literature reports describe the detection of thermal degradation
products of two synthetic cannabinoids in traditional toxicological matrices; blood and urine.
Fundamental understanding of the toxic effects of thermal degradation products could assist
forensic toxicologists in assessing intoxication and in development of new assays. This
knowledge could also be of use to the field of medicolegal death investigation and finally in the
broader context of public health and safety.
Proof of thermal degradation product production and ingestion are crucial to set a
precedent for further studies of possible toxicity. The current research utilizes an optimized
pyrolysis methodology, where a predictive model for thermal degradation was established. An
extraction and LC/MS/MS method was validated according to the guidelines set forth by the
Standard Practices for Method Validation in Forensic Toxicology, and the project aids in
achieving research goals on the set out by SWGTOX in August 2014; such as goal 3.1,
Characterization of Toxicants and 3.2 Factors Affecting the Interpretation of Forensic
Toxicology Data.
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Chapter 1: Introduction
1.1 Purpose
1.1.1 Statement of the Problem
In the past few years, notable progress has been made in identifying the metabolites of
synthetic cannabinoids but there are two areas that remain relatively unexplored: 1) the toxicity
and mechanisms of toxicity of these drugs and their metabolites; and identification of common
pyrolytic products and their toxicity1-10. The latter is critical given that the most common mode
of ingestion of the synthetic cannabinoids is smoking or heated vapor generation. Of particular
concern to forensic toxicology, medicolegal death investigation, and public health and safety are
the acute toxicities of these compounds. The goal of this research is to provide foundational
knowledge to these communities and to provide a framework for developing new diagnostic and
analytical tools for use in the context.
Synthetic cannabinoid products act on the same receptors as Δ9-tetrahydrocannabinol, the
active ingredient within cannabis; however, they produce acute toxic responses that are not
observed with the use of THC11-16. The side effects are considered the “cannabinoid tetrad”,
which includes (1) hypothermia, (2) analgesia, (3) catalepsy and (4) suppression of locomotor
activity17-23. Toxic effects outside of the tetrad also are observed in the renal, cardiovascular,
respiratory and nervous systems. The increased use of these products and the accompanying
dangers to users led the Drug Enforcement Agency to begin temporarily scheduling compounds
such as JWH-018, JWH-073, JWH-200, CP-47,497 and CP-47,497-C8 homologue as Schedule I
compounds under the Controlled Substances Act. Since then, additional compounds have been
added in over the years, and to date, there are 33 Schedule 1 synthetic cannabinoids15, 20-21, 24.

1

Synthetic cannabinoids appeared in the mid-2000s primarily in Europe and soon
thereafter in the United States11, 15, 25-27. In 2009, a number of countries in Europe and the United
States analyzed seized so-called “Spice” products, and numerous synthetic cannabinoid products
such as JWH-073, CP 47,497 and HU-210 among others were detected in these products11. In
subsequent years, a large influx of synthetic cannabinoid products were introduced and became
widely available which in turn led to an increased reporting by poison control centers and
hospitals of synthetic cannabinoid ingestion26, 28. In 2010, there were 2,906 suspected cases
reported and 6,968 in 2011. The number decreased in 2013 (2,668) and increased again in 2014
(3,677)29. Driving while intoxicated, overdose, and death cases that are unknowingly related to
synthetic cannabinoid ingestion may not be accurately reflected in these statistics.
The synthesis of THC analogs dates back to the 1960s when this family of drugs was first
explored for use as pain relieving agents. Unanticipated acute toxic effects resulted in an end to
this work and research attention turned to employing these compounds as research tools for
understanding the structure of cannabinoid receptors and their receptor-ligand binding11, 13, 15, 30.
In the 1970’s, Pfizer developed synthetic cannabinoids commonly termed cyclohexylphenols
(CP), which are considered “non-classical” due to their lack of the benzopyran core of classical
cannabinoids11, 13. In the 1990’s, John W. Huffman began synthesizing the aminolkylindole
synthetic cannabinoids (AAI), which contain napthyl and indole groups. This family of
compounds is identified by the JWH moniker11, 13, 26, 31-32.
THC is an agonist for both the CB1 and CB2 cannabinoid receptors with roughly
equivalent binding affinities for each. THC has a CB1 binding affinity of 41nM, while early
generation compounds JWH-018 and JWH-073 are 9nM and 8.9nM, respectively33. CB1
receptors are located in the central nervous system, which produce the psychological effects
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observed in cannabis users11-12, 14. Synthetic cannabinoids are structurally different than THC but
still elicit similar psychoactive responses to THC11-14, 16, 22, 34. They also bind to the cannabinoid
receptors, and the binding affinity of common synthetic cannabinoids is higher than that of THC.
The increased potency has been reported to cause increased dependence over time and possible
chronic health risks35. The primary route of ingestion for these compounds is the inhalation of
heated vapors. This immediate bioavailability through absorption in the lungs coupled with the
higher binding affinity for the CB1 receptors and potency put users in risk of over dose,
particularly naïve users36.
Recent work in forensic toxicology in the context of synthetic cannabinoids has focused
on analytical assays. Methods have been published for detecting synthetic cannabinoids along
with their respective metabolites in toxicological matrices using hyphenated chromatographic/
mass spectrometry instrumentation and immunoassays15, 22, 29, 31, 37-44. What is lacking from the
current literature are reports and data describing these toxicants associated with the synthetic
cannabinoids and associated pyrolytic products, their mechanisms of action, and how this
information could be used to inform the interpretation of forensic toxicology data. In a 2012
publication, Wiebelhaus and Poklis et al. concluded that, “The increased potency of JWH-018
compared to THC, the variable amount of drug added to various herbal products, and unknown
toxicity, undoubtedly contribute to public health risks of synthetic cannabinoids”45.
Additionally, in a 2011 article published in Clinical Biochemistry, Penn and Langman et al.
stated, “The compounds were also extracted by boiling rather than vaporization into smoke,
which raises the question whether smoking would generate pyrolysis products different from the
parent drug”46. Numerous pyrolytic products produced from the pyrolysis of the synthetic
cannabinoid JWH-018 have been identified26.
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To the best of our knowledge, there has yet to be an extensive investigation into the
ingestion and toxicity of the pyrolytic products produced when smoking synthetic cannabinoids.
In a 2014 paper, Daw and Grabenauer et al. stated, “Synthetic cannabinoids degrade to other
products when smoked. These pyrolysis products can be components that have an altered affinity
to the CB1 and CB2 receptor or entities of unknown pharmacology and toxicology”47. There
have been a few studies into the cell toxicity of synthetic cannabinoid parent compounds, and
these can be used as a basis for advancing and expanding work into pyrolytic compounds as they
are demonstrated to be ingested. Understanding the toxicity of the pyrolytic compounds could
aid in filling the gap of toxicological knowledge regarding acute and chronic toxicity of synthetic
cannabinoids and the associated issues related to forensic toxicology, medicolegal death
investigation, and public health.
1.1.2 Review of Research Literature
One of the earliest studies that detected the presence of synthetic cannabinoids in an
herbal incense product was in 2009, where the authors smoked a cigarette containing one of
seven products they had collected25. Observations of the subjects were documented and several
blood and urine samples were collected over time. The main synthetic cannabinoid detected in
blood was the CP-47,497-C8 homologue. Subsequent analyses of the collected products, led to
the discovery that JWH-018 was present in a number of the products. Pharm-THC, a licensed
German company which produces and distributes Dronabinol®, went on record shortly after the
report as saying they too had isolated JWH-018 from various seized Spice products11, 28.
After these initial findings were publicized, a surge in research focusing on the analysis
and detection of synthetic cannabinoids followed. In 2010, Teske et al detected JWH-018 in
serum of two human subjects, but noted that after three hours, it was nearly undetectable by
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liquid chromatography tandem-mass spectrometry (LC-MS/MS)48. Around the same time, two
studies in Germany were conducted over a two year span to monitor the components found in
herbal products. More than 140 samples were analyzed from June 2008 to September 2009
using GC-MS. Of the samples analyzed, 41 were found to contain no known synthetic
cannabinoids, 28 were found to contain JWH-018, and 35 were found to contain JWH-07349-50.
Sobolevsky et al. were one of the first to report the detection of urinary metabolites of JWH-018
using gas chromatography tandem-mass spectrometry (GC-MS/MS) and LC-MS/MS1. Urine
samples were collected and analyzed by police from three individuals who confessed to using an
herbal incense product within 12 hours of being arrested. GC-MS/MS tentatively identified two
metabolites, while LC-MS/MS revealed another 11 tentative metabolites. The authors noted that
no detectable amount of parent drug was present in the urine samples.
The major metabolites of JWH-018 were determined in 2010 by in vitro phase I
metabolism followed by Moller et al. reporting the findings from a study which screened
approximately 7500 urine samples for JWH-018 and/or its metabolites for the purpose of human
doping controls in 20112, 51. Subsequently, the World Anti-Doping Agency specifically added
products containing the synthetic cannabinoid JWH-018, JWH-073, and HU-210 to their 2012
list of prohibited substances for athletes52.
In 2011, the group from Germany fully validated a LC-MS/MS method for the analysis
of multiple synthetic cannabinoids, including JWH-018 and JWH-073. It was applied to
approximately 100 serum samples provided from hospitals, police authorities, and rehabilitation
centers, and the findings showed that after being banned by German legislation in 2009, JWH018 and JWH-073 were still found among products being sold. Of the 57 samples which tested
positive for at least one synthetic cannabinoid, nine of them were positive for JWH-018, and six
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were positive for JWH-07353. The validation of cannabinoid detection methods continues still, as
in 2016 an LC/MS/MS method was reported that encompassed 32 synthetic cannabinoids54. Not
long after, supplementary methods from both blood and urine specimens were published55-58.
Papers using GC-MS and LC-MS/MS were published by Grigoryev et al. which reported
the detection of metabolites corresponding to JWH-250 as well as JWH-018 and JWH-073 in
human serum, human urine, and rat urine4-5. The human serum and urine samples were collected
from arrested individuals that confessed to using herbal incense products and analyzed within 24
hours of arrest. A number of structures were tentatively identified as metabolites of the three
synthetic cannabinoids, but no parent drug was present in detectable amounts, highlighting the
need for assays which are capable of detecting the metabolites of these drugs4-5. Later in 2011,
the first LC-MS/MS studies using authentic standards to quantify the metabolites of JWH-018
and JWH-073 in human urine were published59-60. The more recent reports on newer generation
cannabinoids shifted toward the use of hepatocytes for metabolic profiling, and the compounds
analyzed included ADB-PINACA, 5F-ADB-PINACA, MAB-CHMINACA, MDMBFUBINACA, and ADB-FUBINACA61-63. An interesting report from 2016 allowed rats to inhale
synthetic cannabinoids vapor and found that changes in dopamine and serotonin in brain
microdialysates was observed, which could lead to neurotoxicity64.
The next step in research was to understand the binding affinity and activity of the
synthetic cannabinoids. Brents et al. hypothesized that the seemingly unexplained side effects of
synthetic cannabinoids were due in part to the metabolites of JWH-018 not being deactivated.
Upon examination of the six recognized JWH-018 metabolites, the authors found that one of the
metabolites had the same binding affinity as JWH-018, which is almost 10-fold higher than
THC, while four others had binding affinities nearly equivalent to that of THC3. A second paper
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studied the binding of CP47,497-C8 and JWH-073. The authors found that both compounds had
comparable affinity and activity at CB1 as the previous mentioned study found with JWH-01814.
Later in 2013, a study compared the relative activities of a few synthetic cannabinoids and found
that they declined in the order of JWH-122 > JWH-018 > JWH-210 > JWH-073 > THC43. Even
more important for the current work is the 2017 finding of the UR-144 degradant maintaining a
4-fold higher binding affinity at CB1 that even that of its parent compound65. This was supported
by Thomas et al. who investigated JWH-018, XLR-11 and PB-22’s activity at both the CB1 and
CB2 receptors66.
Poklis et al. reported the first detection and disposition of JWH-018 and JWH-073 in
mice after inhalation of a common herbal incense product, “Magic Gold,” in 2011. Five mice
were sacrificed after 20 minutes and another five after 20 hours with both blood and brain
samples being collected for subsequent analysis. Using an LC-MS/MS assay, it was determined
that blood concentrations were lower than in a similar experiment using THC, while an
equivalent concentration was found in the brain45. Another LC-MS/MS study, investigated the
detection and disposition of JWH-018 in mice after inhalation of a different herbal incense
product, “Buzz.” This study determined the concentration of JWH-018 in the blood, brain, and
liver of six mice sacrificed 20 minutes after exposure67. A third study, which sought to describe
the behavioral effects observed after inhalation of the herbal incense product, “Buzz”, in mice,
found that the effects from “Buzz” were similar to marijuana in terms of magnitude and time
course; however, equal doses of both substances yielded considerably lower brain levels of
JWH-018 than THC. The authors concluded that the increased potency of JWH-018 compared to
THC, combined with the variable amount of drug in many products, undoubtedly contribute to
its risks45.
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A few studies have been completed in vitro to determine metabolic products of JWH-018,
JWH-073, CP47, 497 and a newer generation compound, XLR-11. Typically, liver microsomes
are used as the main cell line in the studies9, 68-69. The most directly applicable to the research
proposed here identified 13 phase 1 metabolites from JWH-01868. Another study indicated that
some phase 1 metabolites could be conjugated70. This research however aims to move into the
realm of pyrolysis. Several drugs have been evaluated via pyrolysis including several in our
laboratory7, 42, 71-87. In the 1970s and 80s, the focus was on PCP, heroin and cocaine and later
moved into methamphetamine and fentanyl75, 86. Recently a few reports were found on the
synthetic cannabinoid UR-144 and a designer stimulant, mephedrone. A recent publication
reviews various classes of drugs of abuse and their pyrolytic products that have been identified
throughout the years10. However, only four studies have been found dealing with the metabolism
of a pyrolytic product. The first three utilized the compound, UR-144, and the results of the
study demonstrated that the pyrolytic products have independent metabolic pathways and thus
can have additional toxicological properties. The pyrolysis products and their metabolites are
indicated by GC-MS, LC-MS/MS, NMR, and LC-QTOF-MS7, 42, 72. Another study examined
XLR-11 and its thermal degradation product, where the results show that the metabolites of the
thermal degradation product were more prevalent than that of the parent compound88. These
findings support the hypothesis underlying this proposed work that the pyrolytic products play a
significant role in the context of intoxication, acute and chronic toxic effects, and potentially
lethal toxic responses.
Three papers in 2014 were published evaluating the toxicity of synthetic cannabinoids.
The first investigated CP-47,497-C8, and the authors used buccal and liver cells to determine the
concentration in which toxicity is observed89. The paper indicated that the drug caused
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interference with protein synthesis leading to membrane damage as well as DNA damage at
concentrations of ≥7.5µM and ≥10µM, respectively89. The second paper reviewed the toxicity of
K2 products emphasizing that synthetic cannabinoids have higher potency and efficacy
compared to THC, the synthetic cannabinoids have synergistic effects and that the metabolites
maintain high affinity and activity at the CB1 and CB2 receptors90. The final paper evaluated the
toxicity in brain cells. The authors first found that cell death was observed in a concentration
dependent manner and that the cell death was triggered by the caspase-3 cascade. By the use of
CB1 and CB2 inhibitors, they also determined that the apoptotic pathway was controlled by the
binding and activity at the CB1 receptor. Overall, the peak toxicity began at 2 hours after dosage
and followed a CB1 mediated caspase-3 apoptotic cascade leading to neuronal damage and cell
death91.
Only recently has research been able to dive into the pharmacology of synthetic
cannabinoids due to the rapid generations of new compounds. In 2016, an investigation focused
on the tert-leucinate compounds such as 5F-AMB, and the authors utilized in vivo studies to
demonstrate higher potency than that of earlier generation compounds. Additionally, they found
that hypothermia was reversed by a CB1 antagonist, but not with CB292. In 2017, a review was
conducted on the neurological effects of synthetic cannabinoids, and supported the notion that
such drugs produce dependence93.
1.1.3 Goals and Research Design
The aim of this project was to examine the process of thermal degradation via the
smoking process to understand the scope at which the products may affect analyses. The issues
of synthetic cannabinoid toxicity acting as the major influence on the research and fully
understanding the thermal degradation process are crucial due to the main mode of ingestion,
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smoking. There are current gaps in our understanding of cannabinoid effects including the
mechanism of toxicity, and hypotheses span from unknown pharmacological activity to the
observation of symptom overlap with serotonin syndrome. This research was conducted to
determine the products, evaluate their presence in toxicological specimen and assess their
possible connection to the additional toxicity of cannabinoid use observed.
The research design had three major phases; 1) Develop a pyrolysis apparatus and
methodology 2) Determine the production of various thermal degradation products 3) Evaluate
the presence of degradants in toxicological specimen. An apparatus with the capability to
produce and collect the pyrolytic products across the volatility range within the means of the
laboratory was the first step, and is outlined in Appendix B. After the apparatus was optimized,
the second phase was to pyrolyze various synthetic cannabinoids and identify the thermal
degradation products. This phase of the project is described in chapter 2, and indicated a few
common breakdown pathways to be used as a predictive model. The final phase was to evaluate
the degradants presence in a toxicological specimen in order to establish that such products are
not just produced, but also ingested. Chapter 4 outlines this investigation, and the detection of
pyrolytics in blood samples is a strong indicator that such products cannot be dismissed in
synthetic cannabinoid assessments.

1.2 Instrumentation
1.2.1 Gas Chromatography – Mass Spectrometry (GC/MS)
Gas chromatography – mass spectrometry has been a staple in the field of forensic
science for years. A GC/MS instrument is utilized as a confirmatory analysis by GC separation
of sample analytes and MS interpretation for analyte identification. The components of a GC/MS
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are displayed in Figure 1.1, including a carrier gas, sample injector, column contained in an
oven, ionization source, mass analyzer, an electron multiplier and a data analysis system.

Figure 1.1 – Schematic of a gas chromatograph – mass spectrometer
The carrier gas and sample are injected into the column, which is held within a oven with
controlled heat. As the heat is applied, the analytes within the sample are volatilized based on
their individual properties, and separation is achieved as the analytes are carried through the
column based on the partitioning of interaction between the mobile and stationary phases. The
stationary phase is commonly a polysiloxane derivative that coats the inner walls of the silica
glass capillary column, and the thickness can range from 0.5 to 5 µm. The oven that houses the
capillary column is temperature controlled, which allows for temperature programming to
facilitate separation. At lower temperatures, highly volatile analytes continue to flow, and as the
temperature is ramped, the lower volatile analytes will begin to flow with the carrier gas.
As analytes elute off of the GC column, they are directed into the mass spectrometer.
Ionization of the analytes occurs upon introduction, and this is commonly achieved by electron
11

impact ionization (EI). In EI, the gaseous analytes are ionized via electron bombardment,
typically at 70 eV, and the high-energy electrons cause the analyte to lose electrons and fragment
due to the relaxation of the analyte from excited vibrational and rotational states. At this stage,
there are charged fragments of various m/z, which are focused into the mass analyzer.
There are different types of mass analyzers, but the most common and type used in the
studies of chapters 2 & 3 is a quadrupole. A quadrupole is comprised of four cylindrical rods
arranged in parallel fashion with dc and ac (RF) voltages applied across each. The ions travel
through the space between the four rods, and the voltages on the rods are simultaneously
increased and alternated. This produces an oscillating trajectory onto the ions, which allows for
separation of the ions based on their m/z ratio. Upon exiting the quadrupole, the ions enter a
detector, typically an electron multiplier, which amplifies and converts the ions into an electronic
signal. The entirety of the mass spectrometer components is held under vacuum to ensure a free
path of the ions throughout. The GC/MS analysis provides a chromatogram of retention time vs
signal intensity, and a mass spectrum of m/z versus abundance.
1.2.2 Liquid Chromatography – Tandem Mass Spectrometry (LC/MS/MS)
Liquid chromatography has become the standard technology in the field of forensic
toxicology. LC/MS/MS analysis is a powerful confirmatory methodology, and a generic
schematic is shown below in Figure 1.2. The mobile phase is comprised of different solvents
that vary from aqueous based to more organic. A gradient mixture of the two solvents is used to
elute analytes that are more soluble in either the aqueous or organic based solvent. Commonly,
the initial mixture if highly aqueous, and throughout the gradient, the organic portion is increased
over time before returning to the initial conditions.
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Figure 1.2 – Schematic of a liquid chromatograph

As the solvent are pumped towards the column, the injection valve is important in
controlling sample volume before injection onto the column. Figure 1.3 outlines a common
valve and the two settings used to control the flow of solvent/sample to waste or to the column.
As shown by the different numbered circles, there are 6 different ports, and the inner connecting
channels can rotate to connect different ports as seen in contrast between A and B. Initially, the
channels are connected as in A. In this position, the mobile phase in channeled to the column
alone with no sample. At this time, the sample is being flushed into the sample loop and
eventually to waste. This is where the sample volume is controlled, as based on the sample flow,
the desired sample volume will be pumped into the sample loop. Next, the channels switch to
position B. Now, the mobile phase is pumped into the sample loop, which in turns forces the
previously place desired sample volume from the sample loop to be introduced onto the column.
The analytes within the sample are then separated based on their tendency to interact with the
column and mobile phase gradient.
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Figure 1.3 – Schematic of an LC injection valve. A: Flow setting to fill the sample loop with
desired volume. B: Flow setting to flush sample volume out of the loop and onto column.

LC columns are manufactured in multiple ways to advantageously separate different
types of analytes by placing different propertied chemical groups on the the silica packing. The
most common type of column is a C18 column, which is a chain of 18 carbons producing a nonpolar stationary phase. Depending on the desired separation, columns with other groups such as
phenyls can be can be utilized. In the studies within chapter 4, a common C18column was used
for a reverse phase based separation. The column also vary in length and packing , which
produces smaller pore sizes for mobile phase flow or a longer separation time if necessary. The
specifics of the column used in the current study are outlined in chapter 4.
After separation is successful by the column, the analytes are introduced into the mass
spectrometer, in which this case was a triple quadrupole tandem mass analyzer. Tandem mass
spectrometers are classified into two categories; tandem-in-space or tandem-in-time. The
instrument utilized in the current research is the most common, tandem-in-space instrument. The
basic components of a triple quadrupole mass spectrometer instrument, depicted in Figure 1.4,
are an ion source, three quadrupoles, and a detector.
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Figure 1.4 – Schematic of a triple quadrupole mass spectrometer
The ion source in this instrument employs electrospray ionization, ESI, source, which is a
soft atmospheric pressure ionization technique in which ions transfer from solution into the gas
phase. This technique uses differential pumping from atmospheric pressure to high vacuum,
which is desired to allow for free movement of the analytes through the quadrupoles.
Solution at a flow rate of 1-20 µL min-1 enters into a stainless-steel capillary held at a
high potential of 3-4 kV. Upon exiting the capillary, the emerging liquid is under the influence
of an electric field, causing charge separation. At the voltage in which pressure overcomes
surface tension, a Taylor cone is formed and charged liquid emerges as droplets flowing in the
direction of the counter electrode. A heated transfer capillary or curtain gas drives solvent
evaporation. Solvent continuously evaporates and the electric field of the droplet increases as a
result of the decreasing radius causing the droplets to undergo Coulomb fission repeatedly until
ion formation. There are two models used to describe the formation of ions from charged
droplets; charged-residue model (CRM) and ion evaporation model (IEM). The CRM describes
the formation of ions through solvent evaporation and declustering. Conversely, the IEM model,
describes the formation of ions through desorption from the droplet surface.
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Once formed, the ions flow through the orifice of the curtain plate into the first
quadrupole, where the first stage of separation occurs. A quadrupole separates masses in the
fashion described previously in Section 1.3.1. It is here, in the quadrupole, that precursor ions
are selected. The precursor ions then enter the second quadrupole, which is used as the collision
cell, where ions interact with collision gas to produce product ions. This process, called collision
induced dissociation, CID, occurs and the resulting product ions pass into the third and final
quadrupole for the second stage of mass separation. The ions are then detected and a tandem
mass spectrum is produced. The ions are lastly detected and produce a tandem mass spectrum.
Multiple reaction monitoring, MRM, was utilized to scan for multiple sets of transition ions for
each analyte of interest. In using this method, it can further confirm the identification of an
analyte by the observance of each transition and in the proper ion ratio.
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Chapter 2: Qualitative Analysis and Detection of the Pyrolytic
Products of JWH-018 and 11 Additional Synthetic Cannabinoids in
the Presence of Common Herbal Smoking Substrates
This section of the research project evaluated the thermal degradation of 12 synthetic
cannabinoids. It is important to state that the majority of the identifications in the below
manuscript are tentative identifications based on any combination of a NIST library search match
with a score of ≥75, a mass spectrum analysis or based off of similarity to another reference
standard, which is further described in this preface. There were a number of the pyrolytic
products that were able to be confirmed with a reference standard, however as most of these
products have yet to be identified, there was a lack of reference standards available. Table 2.1
below indicates the method of identification for the 52 thermal degradation products observed,
and more detailed explanation of this process follows.
Table 2.1 – Overview of the identification method for the thermal degradation products observed
in the chapter 2 manuscript. If not indicated as confirmed, it is a tentative identification.
Pyrolytic Product
3-Hydroxyindazole
N-(1,2-dimethylpropyl)-Cinnolinamine
1-Methylcyclohexanylindazole
1-methylcyclohexanyl-N-(valinamidyl)-Cinnolinamine
1-Methylcyclohexanyl-3-Cinnolinamine
1-Methylbenzylcinnoline
1-Pentylindazole-3-carboxaldehyde
penten-4-yl-AB-PINACA
1-(5-fluoropentyl)-Indole
1-(5-fluoropentyl)-Indole-3-carboxaldehyde
3-Benzoylindole
1-(5-fluoropentyl)-3-Benzoylindole
3-Oxindole
1-Naphthalenecarbonitrile
2H-1-Benzopyran-2-one
Methoxynaphthalene or 2-methyl-Naphthol
Naphthol
1H-Indole-3-ethanol

Method of Identification
Based on Indazole NIST Hit
Mass Spectrum Analysis
Mass Spectrum Analysis
Mass Spectrum Analysis
Mass Spectrum Analysis
Mass Spectrum Analysis
Mass Spectrum Analysis
Based on AB-PINACA Standard
Mass Spectrum Analysis
Mass Spectrum Analysis
Mass Spectrum Analysis
Mass Spectrum Analysis
Confirmed
Confirmed
Mass Spectrum Analysis
Based on Naphthol Standard
Confirmed
NIST Library Match
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penten-4-yl-JWH-018
1-butyl-Indole
1-butyl-Quinoline
1-Butylindole-3-carboxaldehyde
1-butyl-3-Acetylindole
buten-3-yl-JWH-073
penten-4-yl-JWH-081
1-Pentylquinoline
N-penten-4-yl-JWH-210
3-(1-methylnaphthoyl)-Indole
N-propyl-3-(1-methylnaphthoyl)-Indole
UR-144 Degradant
1-(5-fluoropentyl)-Indole-3-carboxaldehyde
XLR-11 Degradant
Naphthalene
Quinoline
Formylvaline amide
Indole
Methylindole
Hydroxyquinoline
4-Hydroxycinnoline
4-Cinnolinamine
1-Pentylindole
1H-Indazole-3-carboxaldehyde
1-Pentylisatin
N-(2-methylpropyl)-4-Cinnolinamine
1-Pentylindole-3-carboxaldehyde
1-pentyl-3-Acetylindole
(1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)-Methanone
1-Methylindazole
1-Methylindazole-3-formamide
N-methyl-3-Naphthoylindole
N-phenyl-1-Naphthamide
3-Naphthoylindole
JWH-018

Based on JWH-018 Standard
Based on Indole Standard
Based on Quinoline Standard
Mass Spectrum Analysis
Mass Spectrum Analysis
Based on JWH-073 Standard
Based on JWH-081 Standard
Based on Quinoline Standard
Based on JWH-210 Standard
Mass Spectrum Analysis
Mass Spectrum Analysis
Confirmed
Mass Spectrum Analysis
Confirmed
Confirmed
Confirmed
Mass Spectrum Analysis
Confirmed
Confirmed
Confirmed
Confirmed
NIST Library Match
Mass Spectrum Analysis
Confirmed
Based on Isatin Standard
Mass Spectrum Analysis
Mass Spectrum Analysis
Mass Spectrum Analysis
Mass Spectrum Analysis
Confirmed
Mass Spectrum Analysis
Mass Spectrum Analysis
NIST Library Match
NIST Library Match
Confirmed

For the products in which there was no reference standard and no direct library match, a
mass spectrum analysis was carried out based on any structural library hit, a plausible thermal
breakdown from the parent compound and similarity to a reference standard. For example, a
product such as 1-butyl-indole had no reference standard for comparison. Here the mass
spectrum would be compared to that of the indole reference standard to establish a comparable
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fragmentation pattern other than additional fragments above the mass of indole and a parent peak
of an extra 57 Da. Herein it is proposed that the additional 57 Da is from a butyl chain bonded to
the indole ring. This is supported by the fact that JWH-073 contains a butyl chain on the indole
ring, which was the parent cannabinoid to produce this product. This remains a tentative
identification, and is based on the structure of JWH-073 and observed MS of a reference
standard, indole. This process was carried out on a number of the proposed pyrolytic products,
but further confirmation is necessary. Another method for predicting the identification was to
work off any library search hit. Here, if the library produced a high match probability for a
compound such as indole, but the observed MS has a much higher mass molecular ion peak, it is
clear that the product is not indole itself, though may contain an indole ring. In this case
predictions were based on building possible structures from the parent cannabinoid and with the
indole intact based on the library hit. This is by no means a confirmation, but a basis for the
proposed pyrolytic product, in which further confirmation is necessary in supplemental research.
This project has set the groundwork for identifying pyrolytic products, but is only the first step in
this process. Next, it is needed to be reproduced, and reference standards synthesized to confirm
any of the proposed products in the manuscript below.
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Common Herbal Smoking Substrates. . S. Raso and S. Bell, Journal of Analytical Toxicology 41,
6, 551-558, 2017.
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Synthetic cannabinoids have become a ubiquitous challenge in forensic toxicology and
seized drug analysis. Thermal degradation products have yet to be identified and evaluated for
toxicity in comparison to parent and metabolic compounds. An investigation into these pyrolytic
products, as the major route of ingestion is inhalation, may produce additional insight to
understand the toxicity of synthetic cannabinoids. The pyrolysis of JWH-018 and 11 additional
synthetic cannabinoids and six herbal plant substrates were conducted using an in-house
constructed smoking simulator. After pyrolysis of herbal material alone, the plant substrate was
spiked with the drug compounds to 2-5% w/w concentrations. Samples were collected, filtered,
evaporated under nitrogen gas, reconstituted in methanol, and analyzed via gas chromatographmass spectrometer (GS/MS). Pyrolysis of the plant material alone produced 10 consistently
observed compounds between the six plant species. The pyrolysis of the synthetic cannabinoids
produced a total of 52 pyrolytic compounds, where 32 were unique to a particular parent
compound and the remaining 20 were common products between multiple cannabinoids. The
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thermal degradation followed three major pathways that are outlined to assist in producing a
predictive model for new synthetic cannabinoids that may arise in case samples. The observed
pyrolytic products are also viable options for analysis in post mortem samples and the evaluation
of toxicity.

2.1 Introduction
In recent years, notable progress has been made in identifying the evolving generations of
synthetic cannabinoids and their corresponding metabolites. However, two areas remain
relatively unexplored: 1) the toxicity and mechanism of toxicity of the parent drugs and their
metabolites; and 2) identification of common pyrolytic products and their toxicity1-10. The latter
is critical given that the most common mode of ingestion of synthetic cannabinoids is smoking or
heated vapor inhalation. The acute toxicity of this abuse is of particular concern to forensic
toxicology, medicolegal death investigation, and public health and safety.
Synthetic cannabinoid abuse appeared in the mid-2000s, primarily in Europe and soon
thereafter in the United States11-15. These compounds mimic Δ9-tetrahydrocannabinol (THC), the
active ingredient of cannabis; however, they produce acute toxic responses that are not observed
with the use of THC11, 14, 16-19. The additional side effects, referred to as the “cannabinoid tetrad”
include (1) hypothermia, (2) analgesia, (3) catalepsy and (4) suppression of locomotor activity2026

. Recent work in forensic toxicology in the context of synthetic cannabinoids has focused on

analytical assays, and methods have been published for detecting synthetic cannabinoids along
with their respective metabolites in toxicological matrices using hyphenated
chromatographic/mass spectrometry instrumentation and immunoassays14, 25, 27-37. Lacking from
the current literature are reports and data describing the synthetic cannabinoid pyrolytic products,
mechanisms of toxicity of these species, and how this information could be used in the
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interpretation of forensic toxicology data. At least two authors have expressed the need to
address these research gaps38-39. To date, few pyrolytic products have been identified with only
two being observed in toxicological matrices, UR-144 and XLR-11 degradants28, 40. Further
identification of pyrolytic products may provide insight into the cause of additional acute
toxicities.
The process of smoking is difficult to simulate given that the heated environment is
thermally and chemically heterogeneous. Reaction zones of both oxidative and reductive
chemistry may exist, altered by the process of inhalation. As a result, realistic and reproducible
simulation of ingestion by smoking is difficult. Furthermore, there is no way to establish what
compounds produced by smoking remain in inhaled air for delivery to the lungs and absorption
into the bloodstream. In light of these considerations, exhaustive sampling and collection
methods are a reasonable alternative as a starting point. A number of techniques have been used
for conducting pyrolysis experiments, as summarized in a recent review, and include analytical
pyroprobes, heating in sealed capillary tubes followed by extraction, and solvent
trapping/impinge-like devices10. Each technique is geared toward collecting particular types of
products. When utilizing a capillary tube or any apparatus to contain the sample while heating
followed by extraction, the more volatile products are lost. Conversely, using an analytical
pyroprobe, which connects to a GC inlet via a transfer line, may limit the sampling of the less
volatile materials.
This paper describes results to date of a comprehensive characterization of the pyrolytic
products associated with selected synthetic cannabinoids and six herbal substrates commonly
seen in street samples. The work was accomplished using a device built in-house and designed to
collect as many products as possible, from the most volatile to least. The analytical method was
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optimized using replicate and duplicate analyses starting with herbal mixtures without
cannabinoids. These experiments established compounds that would be expected to arise from
the substrate and to differentiate these from compounds arising from the synthetic cannabinoids.
Using the optimized experimental procedures, each synthetic cannabinoids was characterized.
The results were used to identify common pyrolytic pathways and to develop methods that will
allow for prediction of pyrolytic products of new cannabinoids.

2.2 Methods
The experimental procedures spanned optimizing the constructed apparatus, evaluation of
the designed method protocol, pyrolysis of herbal matrices and pyrolysis of synthetic
cannabinoids. The apparatus was checked for air flow consistency and temperature to ensure
adequate heat was acquired to induce pyrolysis. Initially, the method protocol specifically
regarding sample collection was evaluated to optimize the collection of all pertinent produced
products. Following the method checks, the herbal matrices were pyrolyzed to determine
background pyrolytics, and finally the synthetic cannabinoid compounds were pyrolyzed.
2.2.1 Materials and Reagents
All portions of the apparatus involved directly in the pyrolysis are constructed of quartz
or Teflon to endure high temperatures. Quartz glass tubing was obtained from Quartz Scientific,
Incorporated (Fairport Harbor, OH) in the following sizes: Inner diameter (I) of 1mm, outer
diameter (O) of 3mm and wall width (W) of 1mm; I=7mm, O=9mm and W=1mm; and I=10mm,
O=12mm and W=1mm. Quartz wool was purchased from Acros Organics (New Jersey, USA).
Heat was applied using a Benzomatic® propane torch from Worthington Cylinder Corporation
(Columbus, OH). Pressure levels were controlled with a model VP2S CPS Pro-Set Vacuum
Pump (Hialeah, FL) and a pressure gauge from Valworx Incorporated (Cornelius, NC). The
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temperature was monitored using a HH506RA Multilogger Thermometer, a K-Type
thermocouple and 0.20mm CH+ and 0.20mm Al- wires from Omega Engineering, Incorporated
(Stamford, CT). Sampling utilized 5mL LUER-SLIP plastic syringes and 17mm, 0.45μm syringe
filters from Thermo Fisher Scientific (Waltham, MA) with collection in Methanol from Fisher
Scientific (Hampton, NH). Six herbal species including Nymphaea caerulea commonly called
Blue Lotus, Nepeta cataria or Catnip, Turnera diffusa or Damiana, Zornia latolia or Maconha
Brava, Althaea officinalis or Marshmallow Leaf and Combretum quadrangulare or Sakae Naa
were purchased from Bouncing Bear Botanicals (Lawrence, KS). Synthetic cannabinoid
standards of AB-CHMINACA, AB-FUBINACA, AB-PINACA, AM-694, AM-2201, JWH-018,
JWH-073, JWH-081, JWH-210, MAM-2201, UR-144 and XLR-11 were purchased from
Cayman Chemical Company (Ann Arbor, MI).
2.2.2 Apparatus
The in-house constructed apparatus utilized a T-junction of quartz tubing to contain the
pyrolysis reaction, and positioned into a 250mL Erlenmeyer vacuum flask via rubber stopper so
that the tip of the tube sits in the capture solvent. The flask is connected to vacuum for consistent
air flow producing a light bubbling in the capture solvent. Using the pressure gauge, a setting of
2 inHg was chosen, which equates to 6.77 kPa. A major issue with mimicking the smoking
process is the inherent variability of the process, whether in a cigarette, “joint” or in any version
of a bong. While it is difficult to evaluate how closely a given design mimics a smoking process,
it is possible and essential to record at which temperature pyrolysis takes place. For temperature
monitoring, thermocouple wires were placed in the reaction zone. The wires were kept apart with
plastic coating and inserted through the shorter piece of the T-junction by a series of smaller
quartz tubes held together with a Teflon plug to ensure to wires only came in contact, which
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enables temperature recording, within the reaction zone. A photograph of the constructed
apparatus, schematic information of the T-junction and Teflon plug, and heat signature data is
included in Appendix B.
2.2.3 Sample Preparation
The samples of herbal material needed to preparation, and were weighed out to constant
masses and introduced to the apparatus. Each synthetic cannabinoid sample was prepared
individually over a two to three-day period. The plant material mass was kept constant to ensure
the pyrolysis atmosphere was consistent between trials, and the drug mass used was calculated
thusly to produce a concentration level within the range of 2-5 % by weight in milligrams. The
synthetic cannabinoid standard was dissolved in methanol and sprayed onto the herbal material.
This was conducted with movement of plant material in effort to homogenize spread of the drug
compound. The sample sat overnight to allow the methanol to completely evaporate, leaving the
drug compound behind on the herbal matrix.
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Figure 2.1 – A reproduced MS spectrum of predicted product, N-(1,2-dimethylpropyl)-4cinnolinamine, along with its predicted fragmentation pattern.
2.2.4 Sample Collection
Control samples from the apparatus and unburnt materials were initially analyzed. The
collection method utilizes methanol as the solvent, so unburnt quartz wool and each herbal
species in duplicate were soaked in methanol and analyzed via GC/MS. The quartz wool
produced an equivalent spectrum to a methanol blank as expected. Any observed
chromatographic peaks observed in both samples from the herbal material not seen in either the
methanol or quartz blank were noted, and these background compounds were acknowledged as
being present before herbal material and synthetic cannabinoid pyrolysis and thus not a pyrolytic
product of interest.
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Table 2.2 – Proposed observed pyrolytic products unique to their respectively shown synthetic
cannabinoid
Synthetic
Pyrolytic Product
Cannabinoid
3-Hydroxyindazole
N-(1,2-dimethylpropyl)-Cinnolinamine
1-Methylcyclohexanylindazole
AB-CHMINACA
1-methylcyclohexanyl-N-(valinamidyl)-Cinnolinamine
1-Methylcyclohexanyl-3-Cinnolinamine
AB-FUBINACA
1-Methylbenzylcinnoline
1-Pentylindazole-3-carboxaldehyde
AB-PINACA
penten-4-yl-AB-PINACA
1-(5-fluoropentyl)-Indole
1-(5-fluoropentyl)-Indole-3-carboxaldehyde
AM-694
3-Benzoylindole
1-(5-fluoropentyl)-3-Benzoylindole
AM-2201
3-Oxindole
1-Naphthalenecarbonitrile
2H-1-Benzopyran-2-one
Methoxynaphthalene or 2-methyl-Naphthol
JWH-018
Naphthol
1H-Indole-3-ethanol
penten-4-yl-JWH-018
1-butyl-Indole
1-butyl-Quinoline
1-Butylindole-3-carboxaldehyde
JWH-073
1-butyl-3-Acetylindole
buten-3-yl-JWH-073
JWH-081
penten-4-yl-JWH-081
1-Pentylquinoline
JWH-210
N-penten-4-yl-JWH-210
3-(1-methylnaphthoyl)-Indole
MAM-2201
N-propyl-3-(1-methylnaphthoyl)-Indole
UR-144
UR-144 Degradant
1-(5-fluoropentyl)-Indole-3-carboxaldehyde
XLR-11
XLR-11 Degradant

33

Upon completion of a given burning experiment, three samples are collected from the
apparatus. From the reaction zone, the quartz wool plugs and any leftover ashes are transferred to
a 5mL LUER-SLIP plastic syringe fitted with a 0.45µm filter. The contents are filtered with 5mL
of methanol and collected in a 10mL vial as the first sample. The second sample is also collected
into a 10mL vial after rinsing the T-junction tube with 10mL of methanol. The capture solvent
from the 250mL vacuum flask, which is 50mL of methanol, is transferred to a 100mL beaker as
the third sample. All samples were evaporated under nitrogen and reconstituted in methanol.
The capture solvent was reconstituted to 10mL, transferred to a 10mL vial, re-evaporated and
reconstituted to a final volume of 2mL. The rinse from the tube was reconstituted to a final
volume of 2mL, and the quartz/ashes sample was reconstituted to 500µL.
2.2.5 Instrumental Analysis
Analyses were performed using a Perkin Elmer Clarus 500 gas chromatograph with a
Restek Rxi®-5Sil with Integra-Guard® 30m x 250µm x 0.5µm column coupled with a Clarus
SQ8T mass spectrometer. Helium was used as the carrier gas with a flow of 12.1 mL/min. The
injection volume was a splitless 2µL with the heater set at 275°C. The gas chromatography (GC)
method had an initial temperature of 100°C, ramp of 20°C/min and was held at 320°C for 15min.
The mass spectrometer (MS) was set with a 1.00min solvent delay, scan time of 0.2sec and a
range of 40-500 m/z.
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Figure 2.2 – Breakdown chart of JWH-018 to its proposed observed pyrolytic products; (*)
unique products.
2.2.6 Synthetic Cannabinoid Pyrolysis
Prior to analyzing the synthetic cannabinoids, compounds that arose from pyrolysis of the
herbal material alone were characterized. This process and results are described in Appendix B,
and the results were consistent with previous plant pyrolysis studies demonstrating that the
current methodology is suitable for the present application.
An optimization of experimental conditions was performed to determine the number of
replicates and the number of extractions and rinses necessary to maximize recovery of pyrolytic
products from the synthetic cannabinoids. This was accomplished through a series of 5 replicate
experiments using JWH-018 on Damiana with exhaustive sampling. This sampling schematic is
outlined in Appendix B. Results of these experiments demonstrated that a single wash is
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necessary for both quartz/ashes and tube samples. Additionally, consistent data was observed
through the five trials, and it was determined that three trials was sufficient to acquire all
variations of products. As a result, the remaining JWH-018 trials on the other five herbal
matrices was carried out at an n=3 using only a single rinse for sample collection. Upon
completion of JWH-018 analyses, no differentiation of results was observed between the six
herbal matrices. The remaining 11 synthetic cannabinoid analyses were performed using the
same parameters as JWH-018, but only on a single herbal matrix, Damiana.
2.2.7 Data Analysis
The data analysis stepwise limited the chromatographic peaks of interest to those
consistently observed. Initially, chromatographic peaks were limited to those with a signal to
noise ratio greater than 5, as calculated by TurboMass 6.1.0 software. They were further
narrowed down those consistently present in at least two of the three trials within a retention time
window of +/- 0.05 min. The remaining peaks were noted as a possible pyrolytic product and
evaluated for tentative identification. The identification process is difficult for such products due
to the lack of standards available. Initially, a library search using the National Institute of
Standards and Technology (NIST/NIH) database was carried out to obtain a starting point of a
possible general structure. Mass spectrum analysis was conducted to insure the fragment
breakdown was plausible for the predicted pyrolytic compound, and an example of this is shown
in Figure 2.1. Additionally, the chromatography was evaluated via retention index (RI) where
possible. This combined data analysis along with a logical mechanism of production via
pyrolysis was used to predict compound identifications, but these were not confirmed with
reference materials as they are largely unavailable.
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2.3 Results
2.3.1 Synthetic Cannabinoid Pyrolysis
The pyrolysis trials of the synthetic cannabinoids yielded 52 pyrolytic products, and each
was found to have presence in the smoke as detected in either the tube or solvent samples, with
little to none detected left behind in the quartz/ashes sample. This indicates a potential for harm
as they travel within the inhaled smoke or off to the local atmosphere and may affect an innocent
bystander. Of the proposed pyrolytic products, 32 were unique to a particular parent compound
studied. The unique products might be exploitable as additional markers of synthetic cannabinoid
use even when the parent compound is not detected. Assuming that these pyrolytic products
reach the body and are absorbed, this may widen the scope of toxicological analysis by providing
analytes outside of the typical parent and metabolic compounds. Further studies into the
metabolism, pharmacokinetics and pharmacodynamics are necessary to understand the effects of
these products after production via the smoking process. Table 2.2 lists the suggested products
along with their respective parent synthetic cannabinoid, and Figure 2.2 outlines an example
breakdown of parent to the predicted pyrolytic products. Two important pyrolytics to note were
the degradants of UR-144 and XLR-11, as these are the two previously detected pyrolytics
within toxicological samples, and their presence strengthens the utility of the current method as it
is in agreement with expected pyrolytic compounds previously detected28, 40. Additionally, Daw
et al reported a possible pyrolytic trend of a 2 hydrogen loss at the end of the N-alkyl chain
where present39. This trend was observed here with synthetic cannabinoids AB-PINACA, and
JWH-018, -073, -081 and -210.
Figure 2.2 further illustrates examples of three common breakdown tendencies across the
pyrolysis of all 12 synthetic cannabinoids. The first is a break on either side of the central
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carbonyl group commonly present in synthetic cannabinoids. This breakdown trend produces
pyrolytics such as indole or naphthalene products. The second trend, predictable due to the weak
C—N bond, is the loss of the substituent group bonded to the nitrogen of the indole or indazole
ring structures. An example of this in Figure2.2 is the proposed product, 3-Naphthoylindole, or
other such products such as Formylvaline amide from AB-PINACA and 3-Benzoylindole from
AM-694. The last is the common pyrolytic process of a ring size increase. Majority of synthetic
cannabinoids have either an indole or indazole ring structure, and with the pyrolytic ring size
increase, they convert to a quinoline or cinnoline ring structure respectively. These breakdown or
conversion trends can be used for a prediction model for the thermal degradation of the
continually evolving generations of synthetic cannabinoids.
Separate from the unique pyrolytic products for each cannabinoid, the remaining 20
suggested products were shared between at least two of the parent synthetic cannabinoids
studied, typically similar in structural class. These products are outlined in Table 2.3 and
indicate which parent compounds produced each pyrolytic product. The detection of these
products could not be used to indicate the use of any specific synthetic cannabinoid, but can be
an indication for the use of synthetic cannabinoids in general or possibly limit the search to a
structural class such as naphthoylindoles, indazoles or tetramethylcyclopropyls. Figure 2.3
shows an example breakdown of the different parent synthetic cannabinoids that produced the
pyrolytic, quinoline. It can be noted that each parent compound includes an indole group, and
this type of trend could be exploited to limit a search to those with an indole moiety if quinoline
was detected during analysis if additional information points toward synthetic cannabinoid use.
A limitation here would be other drug compounds that may also share quinoline as a pyrolytic
product, but is still useful as a starting point during investigation.
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Table 2.3 – Proposed pyrolytic products with the parent synthetic cannabinoids they are
commonly produced from; a) AB-CHMINACA b) AB-FUBINACA c) AB-PINACA d) AM-694
e) AM-2201 f) JWH-018 g) JWH-073 h) JWH-081 i) JWH-210 j) MAM-2201 k) UR-144 and l)
XLR-11
Pyrolytic Product
Parent Compounds
Naphthalene
f, g, h
Quinoline
e, f, g, h, i, j, k
Formylvaline amide
a, c
Indole
e, f, g, h, i, j
Methylindole
e, f
Hydroxyquinoline
g, h, j
4-Hydroxycinnoline
b, c
4-Cinnolinamine
1-Pentylindole
f, l
1H-Indazole-3-carboxaldehyde
b, c
1-Pentylisatin
f, l
N-(2-methylpropyl)-4-Cinnolinamine
a, b, c
1-Pentylindole-3-carboxaldehyde
d, e, h, i, j, k, l
1-pentyl-3-Acetylindole
e, h, i, j, k, l
(1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)-Methanone
k, l
1-Methylindazole
a, b
1-Methylindazole-3-formamide
b, c
N-methyl-3-Naphthoylindole
f, g, i
N-phenyl-1-Naphthamide
g, i
3-Naphthoylindole
f, h, j
JWH-018

e, h

2.4 Discussion
Due to the major route of ingestion of synthetic cannabinoids being inhalation through a
smoking process, an understanding of the pyrolytic breakdown of these compounds is important
for full analysis in toxicological samples. Pyrolysis has been studied in the past with different
techniques; however they had the tendency to focus on either the most or least volatile products.
There is lacking data on the majority of products’ volatility, but a few where there is, indicate the
ability of the reported methodology to collect products across the volatility range. A few high
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volatile product examples are indole, quinoline and naphthalene whose vapor pressure levels are
on the order of ~10-2 mmHg41-43. On the other side of the spectrum, low volatile parent
compounds such as JWH-018 and JWH-073 whose vapor pressure is on the order of ~10-10
mmHg were also collected44-45.
The constructed apparatus demonstrated the ability to produce a “smoking-like
environment”, which is important as synthetic cannabinoids are often smoked using an herbal
matrix laced with the compound of interest. Six common herbal materials were pyrolyzed to
determine background products to differentiate from those pyrolytics of synthetic cannabinoids,
and ten consistent products, which were tentatively identified, were detected and consistent with
previous pyrolysis studies on plant material demonstrating the methodology was fit for pyrolytic
analyses.

Figure 2.3 – Chart displaying each parent synthetic cannabinoid that produced quinoline.
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The pyrolysis trials of the synthetic cannabinoids produced fifty two pyrolytic products.
Thirty two of these proposed products were unique to a particular parent cannabinoid compound,
whereas the remaining twenty were shared by multiple parent compounds. The unique pyrolytic
products are important, as they may serve as additional toxicological markers and indicate use of
a specific synthetic cannabinoid without detection of the parent or metabolic compound. The
shared pyrolytic products are not an indication of a specific cannabinoid, but are a useful
suggestion of synthetic cannabinoid use. Another powerful tool for these thermal degradants is
for the analysis of drug paraphernalia for the presence of synthetic cannabinoids. Both the unique
and shared products provide beneficial information to the field, as of now, they are limited to
those synthetic cannabinoids included in the current study. It cannot be said that other
compounds or future generations will not produce equivalent pyrolytics. Further studies are
necessary as well as synthesis of reference standards to confirm the products proposed. To reach
a level of unambiguity of the identification of the proposed products, chromatographic analysis
of reference standards as well as structural analysis via FTIR and NMR will be necessary.
Upon analysis of the studied cannabinoids, three major thermal degradation trends were
apparent including: 1) a break on either side of the central carbonyl; 2) loss of the
indole/indazole N-bonded substituent group; and 3) a ring size increase from indole/indazole to
quinoline/cinnoline respectively. These trends may be used as a predictive model for other
synthetic cannabinoids not studied here, not yet seen in casework, or for future generations yet to
be synthesized.
The current study has set the stage for further investigation into the pyrolysis of synthetic
cannabinoids as multiple products have been proposed, which could be utilized in various facets
of forensics. Future steps are to quantify this process as to obtain an idea of the percent
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breakdown of these compounds that can be expected as well as investigating their presence in
biological matrices. If they do in fact reach the body, they may produce toxic effects. The World
Health Organization (WHO) has not classified the proposed products, but other indole,
quinoline, cinnoline and naphthalene based compounds have been classified as group 2B, or
possibly carcinogenic46.

2.5 Conclusion
The reported methodology was demonstrated as a suitable means for pyrolysis studies,
and the performed analyses lay the groundwork for beginning to understand the effect of
pyrolysis on synthetic cannabinoids. Ten pyrolytic products were observed in the herbal
substrate trials, and fifty two pyrolytics were detected from the pyrolysis of the synthetic
cannabinoids. The understanding of how the synthetic cannabinoids thermally degrade, via three
observed breakdown or conversion trends, provides a predictive model to be used on additional
compounds. The proposed pyrolytics also may provide additional analytes to be analyzed in
toxicological samples and for use in toxicity studies.
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Chapter 3: Utilization of Novel Pyrolysis Methodology to Evaluate
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Smoking as a route of ingestion of drugs of abuse is still common amongst users, and this
poses numerous health risks both to the users and bystanders. It is understood that drug
compounds thermally degrade during the smoking process, but knowledge of the effects of such
products is still lacking. This report employs a previously optimized in-house method to
consolidate previously unconfirmed pyrolytic results as well as identify newly observed products
of drugs including cocaine, heroin and phenethylamines. This methodology has already
demonstrated its ability to evaluate the pyrolysis process with a number of synthetic cannabinoid
compounds, and the current opioid crisis led to the movement back to the classical drugs. In the
1980’s, a type of encephalopathy specifically seen in heroin smokers was coined heroin induced
spongiform leukoencephalopathy or HSL. As this effect had a larger observance in smokers
versus injectors, hypotheses of the produced thermal degradants having additional
pharmacodynamic effects arose. After analysis, different previously detected as well as newly
observed degradants were identified. Interestingly, some of the products are even metabolic
products, and the impact the identified products may have span across drug investigations,
toxicological assessment, metabolic evaluations and public health.
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3.1 Introduction
A critical review of thermal degradation studies of drugs of abuse was published by our
group in 20151. The impetus for this project was to consolidate findings to date related to drugs
of abuse such as heroin and cocaine and to provide a foundation for work regarding novel
psychoactive substances (NPSs), primarily synthetic cannabinoids. The fact that these
compounds are ingested primarily by smoking (and now “vaping”) coupled with the
constellation of toxic effects observed has driven this interest. As examples, XLR-11 and UR144 both contain a cyclopropyl group that opens with heating to form known degradation
products referred to as degradants which are detectable in toxicological samples2-5. It is also
observed that these degradants produce a metabolic profile separate from the parent
compound3.This renewed interest in thermal degradation products has benefited from improved
instrumental capability over what was available even fifteen years ago. Accordingly, the goal of
this project was to revisit earlier thermal degradation studies of drugs such as cocaine, heroin,
and phenethylamines using optimized experimental conditions and designs coupled with
improved instrumental detection methods.
While greater attention is being paid to NPSs, these “older” drugs remain a forensic, legal,
and public health challenge. Heroin and related synthetic opioids have become the current
greatest overdose threat. The National Institute of Health (NIH) testified to this issue in front of
the senate, stating a current heroin use population of nearly 1 million6-7. Unlike synthetic
cannabinoids, opioids are ingested by injection, snorting, and smoking, but issues related to
smoking and thermal degradation products has long been a concern. Beginning in the 1980’s, it
was observed that heroin users that smoked the drug had higher mortality rates due to a type of
encephalopathy called heroin induced spongiform leukoencephalopathy, HSL, which was not
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seen in users who instead utilized injection8-26. This led to initial investigations into the pyrolytic
process of smoking illicit drugs and tentative identification of any thermal degradation products.
The current investigation employed a proven in-house method to revisit the pyrolysis of
commonly smoked illicit drugs and demonstrate the production of both previously observed
thermal degradation products as well as several newly identified products27. The findings are
interpreted in the context of current understanding related to the potential toxicity of the thermal
degradation products and effect on metabolite presence interpretation.

3.2 Methods
3.2.1 Materials and Reagents
An apparatus to carry out controlled pyrolysis experiments was constructed in-house and
specifications previously reported27. Sample collection utilized 5mL LUER-SLIP plastic syringes
and 17mm, 0.45μm syringe filters from Thermo Fisher Scientific (Waltham, MA) with methanol
as the solvent from Fisher Scientific (Hampton, NH). Standard solids of methamphetamine,
cocaine, heroin, and fentanyl were obtained from Sigma-Aldrich (St. Louis, MO).
3.2.2 Pyrolysis Trials
Solid reference standards were analyzed individually by being placed directly into the
reaction zone of the previously described apparatus. No additional sample preparation was
required. The reaction zone is enclosed with quartz wool to contain the pyrolysis of the drug
while constant air flow was controlled with the vacuum pump. The pyrolysis study of each
compound was conducted in replicates of 5 with each experiment utilizing 20 mg of reference
standard. Two additional experiments were carried out with a mixture of heroin and fentanyl
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given the current increase in fentanyl/heroin street samples. These mixtures were prepared to be
50 % w/w of each compound.
3.2.3 Sample Collection
After heating, three samples were collected from different locations in the apparatus as
previously described27. Samples were evaporated under nitrogen and reconstituted in fresh
methanol. The capture solvent was initially reconstituted to 10mL, transferred to a 10mL vial,
re-evaporated and reconstituted to a final volume of 2mL. The rinse from the tube was also
reconstituted to a final volume of 2mL, while the quartz/ashes sample was reconstituted to
500µL. Each solid sample resulted in solutions, one from each location and for each drug, 5
individual samples were subjected to thermal degradation.
3.2.4 Instrumental Analysis
Analyses were performed using a Perkin Elmer Clarus 500 gas chromatograph with a
Restek Rxi®-5Sil with Integra-Guard® 30m x 250µm x 0.5µm column coupled with a Clarus
SQ8T mass spectrometer. Helium was used as the carrier gas with a flow of 12.1mL/min. The
injection volume was a splitless 2µL with the heater set at 275°C. The gas chromatography (GC)
method had an initial temperature of 100°C, ramp of 20°C/min and was held at 320°C for 2min
for a total run time of 13min. The mass spectrometer was set with a 1.00min solvent delay, scan
time of 0.2s and a range of 40-500 m/z.
3.2.5 Data Analysis
The first step in the analysis scheme was selection of which chromatographic peaks to
consider. Only those peaks that were consistently present in at least three of the five trials were
selected for further evaluation. A library search using the National Institute of Standards and
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Technology (NIST/NIH) database was carried out to obtain a match or a starting point of general
structure for mass spectrum breakdown analysis. This mass spectrum analysis was conducted to
insure the fragment breakdown was plausible for the predicted pyrolytic compound, and the
chromatography was evaluated via retention index (RI) where possible. This combined data
analysis along with a logical mechanism of production via pyrolysis was used to predict
compound identifications, and these were confirmed with reference materials where available.

3.3 Results
3.3.1 Methamphetamine
The pyrolysis of methamphetamine produced five products Figure 3.1. Among these
products are both previously found and newly observed pyrolytics. The amphetamine was
confirmed with reference standard, while the others were identified by an obtained NIST
database match of at least 75 and reasonable mass spectrum analysis. Amphetamine, N-formylmethamphetamine and N,N-dimethyl-amphetamine were identified in previous studies spanning
from the late 80’s into the 2000’s, which are described in the review paper by Nida and Bell1.
Amphetamine is a central nervous stimulant as well as N,N-dimethylamphetamine, which may
produce an increased effect on the user when smoking methamphetamine. Pharmacodynamic
information of N-formyl-methampetamine is lacking and in need of investigation. On the other
hand, N-acetyl-methamphetamine and N,N-dimethyl-phenethylamine have not previously been
reported as thermal degradation products of methamphetamine. The acetylated product,
compound 4 from Figure 1, has been thought to be an impurity in illicit drug synthesis, but now
appears to be the product of a pyrolytic acetylation process, which could further break down into
previously reported compounds, 1, 2 and 328. Breakdown of compound 2 could lead to the
production of N,N-dimethyl-phenethylamine via demethylation, which is known to be a
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Figure 3.1 – Proposed pyrolytic breakdown of methamphetamine into five pyrolytic
products. M = Methamphetamine metabolite; P = Previously found pyrolytic product
stimulant and mood enhancer used as a flavoring agent. The production of N,N-dimethylphenethylamine through the smoking process could enhance the effect and thus increase the
potential for dependence and addition. These compounds would also follow their own metabolic
and excretion pathways. The para- location on the benzene ring is a common location for
possible hydroxylation between each structure, but the additional methyl, aldehyde or ketone
groups in compounds 2-5 may produce further binding properties as well as supplementary phase
I and II reaction sites. These metabolites would be missed under current assays, as their ion
transitions would differ from commonly monitored transitions in methamphetamine urine
analysis.
3.3.2 Cocaine
In the late 80’s, cocaine pyrolysis began to be examined and two major products
identified were benzoic acid and anhydroecgonine methyl ester, AEME29-30. The current study
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Figure 3.2 – Proposed pyrolytic breakdown of cocaine into eight pyrolytic products. M =
Cocaine metabolite; P = Previously found pyrolytic; M* = Metabolite of a previously
reported cocaine pyrolytic product
also observed and confirmed these two pyrolytic products, while the others were identified using
the NIST database and mass spectrum analysis. Compound 1 is a predicted product based on an
equivalent mass spectrum of tropinone except for the parent peak being 17 Da smaller. This
difference could be explained by the loss of the carbonyl group of tropinone to produce
compound 1. Along with AEME and benzoic acid, two other reported degradants from a 2007
study were present, cocaethylene and norcocaine31. AEME has been reported to induce greater
neurotoxicity than cocaine in a 2012 study, which indicates that other pyrolytics may also
produce added acute toxic effects compared to the parent drugs32. Cocaethylene and norcocaine
have been reported as biomarkers in hair for cocaine abuse, but not directly linked to abuse by
smoking33-34. Four previously unreported products were detected in the current study, which are
outlined in Figure 3.2. Of the newly reported products, two tropinone compounds, 1 and 3, are
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possibly further degradations of earlier observed products. Tropinone is a precursor to atropine,
an efficacious medication for some nerve agents, and its toxicology is not entirely understood,
though is considered a level 2 health risk35. Compound 1, 8-methyl-nortropidine, is a reduction
of tropinone, whose pharmacodynamics effects are unknown. Ecgonine methyl ester, another
newly discovered pyrolytic product is typically seen as a metabolite of cocaine along with a
number of the other detected products, including compounds 4 and 5. Ecgonidine has been
described as metabolic product of the pyrolytic product, AEME, and thus has been useful as a
marker for inhalation as the mode of ingestion when present36. The current study supports that
ecgonidine is a useful smoking marker, but it now may be present even without the necessary
breakdown of other products. The degradants shown here all have multiple sites for metabolic
processes, and extensive studies would be necessary to identify possible metabolites. More
importantly, the numerous products observed provide a basis for toxicological assays and target
compounds in the analysis of drug paraphernalia.
3.3.3 Heroin
Extensive studies on heroin pyrolysis were conducted in the late 80’s and revisited in the
early 2000’s. In the 80’s, four predicted pyrolytic products were observed including compounds
2, 3 and 7 from Figure 3.337. These three compounds are produced via acetylation processes at
the amine chain and phenanthrene ring. Most notable is 6-monoacetylmorphine (6-MAM), which
is the major metabolite of heroin and the targeted marker for the use of heroin in comparison to
morphine. The remaining two have largely been unstudied and unconfirmed, but here, a
proposed GC/MS spectral fragmentation pattern of compound 2 is shown in Figure 3.4.
Sequential deacetylation and dehydration steps are predicted at steps A - D2. At steps D1, E and
F, the breakdown of the ethanamine side chain takes place. The 236 m/z species is a predicted
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intermediate produced as the dehydrogenation of the position 9 hydrogen of the phenanthrene
ring and the ethanamine side chain cleavage is initiated. Compounds 1, 4, 5 and 7 were able to be
confirmed with reference standards.

Figure 3.3 – Proposed pyrolytic breakdown of heroin into eight pyrolytic products. M =
Heroin metabolite; P = Previously found pyrolytic; M^ = Metabolite of a newly reported
pyrolytic product of heroin
Brenneisen and Hasler studied heroin pyrolysis through the inhalation method commonly
termed “smoking the dragon”, where they observed similar products including another major
breakdown compound, morphine38. In addition to these previously detected products, three
additional products were observed including two tentatively identified: normorphine and
nalorphine, and one confirmed: codeine. Normorphine is the major metabolic product of
morphine, but has little opioid activity39. On the other hand, nalorphine is a mixed agonistantagonist at the opioid receptors, and produces side effects such as dysphoria, anxiety and
hallucinations40-41. The third newly observed pyrolytic is codeine. A significant consequence of
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the observed opioid thermal degradants is the vast difference in half-lives in comparison to
heroin. Heroin has a rapid half-life of a few minutes, but the thermal degradants may lead to a

Figure 3.4 – Proposed fragmentation pattern of N,3-O,6-O-triacetylnormorphine, compound
2 from Figure 3.3.
longer duration of action as the additional opiate breakdown compounds, such as nalorphine,
codeine and morphine can have half-lives of multiple hours42-44.
3.3.4 Fentanyl
In the late 90’s, fentanyl, an extremely potent opiate, become a popular drug of abuse and
has recently been a large part of the opioid epidemic with its lacing of heroin street samples.
During the 2000’s, a few pyrolysis studies were conducted, which determined that fentanyl is
thermally stable up to approximately 500°C, but at higher temperatures, pyrolytic products began
to be observed45-46. In Figure 3.5, there are a number of these products that were also identified
in the current study, shown as compounds 1, 2, 4 and 6, with 2 and 6 being confirmed.
55

Despropionyl fentanyl is also a metabolic product of fentanyl as well as a common precursor in
fentanyl synthesis, but the pharmacologic activity of this compound is thought to be lower than
that of the parent47. Another earlier noted compound also observed here is 1-phenethylpyridium
(1-PEP), though has not been confirmed via reference standard in any of the studies46. The next
consistently observed pyrolytic between studies is compound 2, N-phenyl-propanamide, which is
also known as propionanilide. Propionanilide has been reported as a possibly harmful agent if
orally consumed as noted by the international Globally Harmonized System of Classification and
Labelling of Chemicals (GHS)48. Two newly found pyrolytics were tentatively identified and
include the methyl ester of propionanilide and bibenzyl. GHS labels bibenzyl as a category 1
chemical if entered into airways, which is a pertinent danger to any user and bystanders who may
inhale the vapors49. The last major product observed was norfentanyl, which is both a previously

Figure 3.5 – Proposed pyrolytic breakdown of fentanyl into six pyrolytic products.
M = Fentanyl metabolite; P = Previously found pyrolytic
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detect pyrolytic as well as an observed metabolic product of fentanyl1. It has been reported that
the ratio of fentanyl to norfentanyl can be beneficial in determining if there was an acute fentanyl
toxicity or chronic fentanyl utilization50. This ratio is believed to be >8 for acute toxicity, but this
value is based on a route of ingestion other than smoking. This would need to be evaluated with
smoking to ensure confidence in diagnosing acute toxicity in such instances. This is just one of
numerous areas of impact where fully understanding the smoking process is necessary.

3.4 Discussion
Due to differing toxic effects seen in users of the same drug but with different routes of
ingestion, it had been hypothesized in the past that the abuse of a drug may become more toxic
when smoked in comparison to other routes of ingestion. An example of this is HSL and had
been briefly examined. Research in this area had begun to lose interest due to an absence of
necessary instrumentation capabilities and limited results. The idea has been rejuvenated with an
investigation of the pyrolysis with synthetic cannabinoids as their acute toxicity is not
understood, and led to a revisit of these still abused classical drugs. The production and ingestion
of additional compounds unbeknownst to the user could be a cause of the further toxicity, and a
complete understanding of the scope of thermal degradation is vital. The knowledge of the
presence of specific pyrolytic products allows for toxicity evaluations, a larger analyte pool for
drug investigations and novel metabolic investigations, which may affect current timelines used
to estimate dosage events.
The first impact to consider is the pharmacologic effects and toxicity the identified
products may induce. This concept is supported by the high mortality rate of heroin smokers due
to HSL in the 1980’s. As the thermal degradation products are identified, the evaluation of their
toxicity and their individual impacts can be researched. The thermal degradants can be smaller in
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size and more lipophilic, which both could increase the compounds ability to enter the blood
stream and interact with receptors throughout the body. The same receptors as the parent drug
may be the sites of action, but depending on the structure of the degradant, they may interact
differently and in new sites. Studies on the prevalence of the thermal degradants to be ingested,
binding affinity evaluations and toxicological assays are interesting avenues of research that stem
from the knowledge of the re-confirmed and newly identified products.
Another advantage of knowing these products to consider is within drug investigations.
Drug paraphernalia collected as evidence can now be further processed. If a drug was smoked in
set paraphernalia, it is unlikely that the parent compound would remain, but the thermal
degradants may be left behind. After this report, more analytical targets are available for the
processing of such evidence with simple collection and analysis techniques that common
laboratories could implement. Detection of the pyrolytic products may give investigators a
starting point for their investigations, and may lead to the request of the appropriate toxicological
testing, as not all precincts may have the monetary ability for wide spectrum testing. Having
additional information at their disposal, more options will be available to use to decipher
appropriate actions and conclusions within both criminal and public health cases.
An interesting finding is the presence of metabolic products as thermal degradation
products. This can have a resounding effect on the interpretation of toxicological assays.
Metabolites are typically used as markers of a parent drug and based on studied pharmacology, a
dosage time and concentration can be extrapolated. However, if these products are produced at
the dosage event via smoking, this affects how those interpretations can be made. Secondly, the
thermal degradants open the possibility for additional sites for phase I and II metabolism, and
will have unique metabolic products. As metabolic profiles can be established for the thermal
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degradants, these metabolites may be detected for a longer time period and be used as additional
markers for the smoking of a drug compound. The pharmacologic data of the thermal degradants
will have to be added to current knowledge of parent drugs for accurate dosage estimates as well,
as the concentration of known metabolites is no longer zero, but the amount of the compound as
a pyrolytic that is ingested along with the parent.

3.5 Conclusion
The current study has reconfirmed the production of many thermal degradants that had
been previously reported as well has detected a number of newly observed pyrolytics using the
methodology previously reported. The observed products can be useful in analyzing drug
paraphernalia, provide novel target analytes in toxicological assays and affect the interpretation
of currently monitored metabolites. As more products are identified, numerous research
opportunities will arise to understand the rate of ingestion, pharmacology, metabolism and
toxicity of each thermal degradant.
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Chapter 4: Detection of Confirmed Thermal Degradation Products
of Ten Synthetic Cannabinoids in Post-Mortem Blood Samples
This chapter is an adaption of a submission to the Journal of Forensic Toxicology in April 2018.
Detection of Confirmed Thermal Degradation Products of Ten Synthetic Cannabinoids in PostMortem Blood Samples. S. Raso and S. Bell.
Permission will be obtained from the co-authors and the Journal Forensic Toxicology according
to the journal’s license’s, copyright and permissions policy. A copy of the permissions agreement
will be shown in Appendix A if obtained before submission to the college.

The vast toxic effects of synthetic cannabinoids have proven difficult to counteract and
fully understand. Adverse effects outside of the common cannabinoid tetrad have been observed
in multiple body systems with various causes of death. A relevant hypothesis to the current study
is the overlap of symptoms with serotonin syndrome. Current research has begun to link the use
of cannabinoids to serotonin syndrome by the finding of thermal degradant products that contain
similar core structures. This leads to the notion that the cannabinoid pyrolytics may have binding
activity at the serotonin receptors, in which causes the toxic side effect of serotonin syndrome.
This report aids in further making this hypothesis a logical possibility. It is the first simultaneous
monitoring of parent synthetic cannabinoids and possible thermal degradation products in
postmortem blood samples. A validated LC/MS/MS method following a liquid-liquid extraction
provided the detection of multiple thermal degradant compounds within the blood samples. The
establishment of the pyrolytic ingestion into the body indicates that they cannot be dismissed in
the evaluation of the toxicity of synthetic cannabinoids. The degradants presence may impact
toxicological assays, metabolic profiles as well as toxic secondhand inhalation of bystanders.
The results presented here direct the need for research into the activity of such degradants,
determination of their metabolic profile, further investigation into the possibility of serotonin
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syndrome, and added testing of postmortem samples for additional pyrolytics as well as
metabolites, which have been observed in previous work on drug pyrolysis.

4.1 Introduction
The prevalence of synthetic cannabinoids is a public health issue due to the diverse toxic
effects produced. It is challenging to effectively interpret the lethality of synthetic cannabinoids,
while also responding to usage outbreaks and identifying new generation compounds. Recently
in New York City, 33 individuals were intoxicated in a single neighborhood, and 18 had to be
hospitalized1. Traditional cannabinoid effects are described using the “cannabinoid tetrad”: 1)
hypothermia, 2) analgesia, 3) catalepsy and 4) locomotor activity suppression, but adverse
toxicity beyond this tetrad are seen in multiple body systems with synthetic abuse2-5. Acute
kidney injury (AKI) is one of the effects observed in the endocrine system, and is often seen in
emergency rooms where synthetic cannabinoid use is coupled with alcohol6-9. Cardiovascular
effects include tachycardia, hypertension, palpitations and even myocardial infarctions10-14.
Interestingly, even the nervous system is affected as ischemic stroke has been reported on several
occasions15-19.
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Figure 4.1 – The structure of serotonin and examples of proposed synthetic cannabinoid
thermal degradants with similar structure.
In recent years, it has been suggested that some of the observed toxic effects overlap with
symptoms of serotonin syndrome20. Serotonin syndrome is caused by an over-abundance of
serotonin. Numerous symptoms including agitation, confusion, tachycardia and seizures are seen
to name a few, but is commonly described as a triad of muscular abnormalities, autonomic
hyperactivity and mental-status changes21. It is a potentially fatal sickness, and may be a toxic
side effect of synthetic cannabinoids22. A previous investigation into the thermal degradation of
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cannabinoids may have provided a missing link to connect cannabinoids to serotonin syndrome.
Numerous suggested pyrolytic products have contained similar core structures to that of
serotonin, which could explain the serotoninic effects, and a few examples are shown in Figure
4.123. The structural resemblance indicates the possibility of equivalent binding capabilities, thus
the abundance of thermal degradants may produce serotonin syndrome like effects.
Based on a global survey in 2017, 59.5% of respondents who ingested cannabinoids did
so in herbal form in comparison to powders, resins and oils. Sixty-six percent of those users
acknowledged smoking the drug via rolled cigarette24-25. Given that smoking primary mode of
ingestion, an understanding of the thermal degradation process and products is important in the
larger context of toxic effects. The high temperatures reached during pyrolysis induce complex
reaction zones where thermal degradation and free radical processes occur. The thermal
degradation of a compound produces any number of supplementary compounds to the parent
itself. Since pyrolysis is a free radical environment, unique reactions are possible including ring
expansions, which are an indication of a pyrolytic process. An evaluation of pyrolysis on illicit
drugs over time via a literature review was conducted in 2014 with intriguing results and
limitations to the performed studies26. Subsequent work by our group has developed a novel
smoking simulation apparatus and pyrolysis method to resolve the apparent limitations and
applied it to synthetic cannabinoids and classical drugs of abuse23.
A notable finding of these studies was the formation of metabolites by thermal
degradation. Metabolite presence is influential evidence to the use of a particular drug. Current
pharmacokinetic models are based off the production of metabolites after the time of ingestion,
but this interpretation must be altered if the metabolite is present at the time of exposure within
the inhaled vapor. It is also important to take into account the activity of the metabolic product.
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As thermal degradants have been demonstrated to be produced, it is crucial to evaluate the
presence of such products within the body to establish their ingestion along with the parent
compounds. To date, the two largely detected thermal degradants are the UR-144 and XLR-11
degradants. A recent study has shown that the UR-144 degradant has a fourfold stronger binding
affinity at CB1 in comparison to the parent drug27. The UR-144 degradant has also been detected
in blood as well as its predicted metabolites in urine28. The XLR-11 degradant was also found to
have its own metabolic profile as the analysis of a known user’s urine produced metabolites
varying from the parent’s profile29. However a small sample size, a clear precedent for thermal
degradants being ingested is set, as these products would not be produced metabolically after the
ingestion of solely the parent drug.
This report is the first to the author’s knowledge of a comprehensive study of postmortem
blood samples for broad spectrum monitoring of thermal degradation products with known
parent drug presence. The obtained blood samples were previously analyzed and found to
contain one or more synthetic cannabinoids. Based on the known cannabinoid the detection of
predicted pyrolytic products was carried out using a validated and optimized LC/MS/MS
method. The results of the study demonstrate that the presence of thermal degradants, including
those with ring expansions only produced at high temperatures, and cannot be dismissed. Further
research is significant as these products will produce their own unique metabolic and
pharmacodynamics profiles.

4.2 Methods
4.2.1 Materials and Reagents
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Each of the solvents used for liquid chromatography analysis including water with 0.1%
formic acid and acetonitrile with 0.1% formic acid were obtained from Thermo Fisher Scientific
(Waltham, MA). The extraction solvents, 0.2M sodium carbonate buffer at pH 9.4, 99:1 hexaneethyl acetate and 50:50 methanol-acetonitrile with 0.1% formic acid were prepared using
solvents from Thermo Fisher Scientific. Synthetic cannabinoid standards of 5F-ADB, 5F-AMB,
5F-PB-22, AB-CHMINACA, AB-FUBINACA, AB-PINACA, ADB-FUBINACA, FUB-AKB48, MAB-CHMINACA and MMB-FUBINACA were purchased from Cayman Chemical (Ann
Arbor, MI). Standards of predicted possible thermal degradation products were obtained as
follows: 4-hydroxycinnoline and 3-hydroxyquinoline from Ark Pharm, Inc. (Arlington Heights,
IL); indazole-3-carboxaldehyde, indazole, indole, quinoline, N-methylindole, 4-methylquinoline
and indole-3-carboxaldehyde from Sigma-Aldrich Chemicals (St. Louis, MO); 1-methylindazole
and cinnoline from Alfa Chemistry (Holtsville, NY); pentylindazole, pentylindazole-3carboxaldehyde, pentylindole and pentylindole-3-carboxylic acid were synthesized by the Dr.
Gregory Dudley research group at West Virginia University. Human blood for validation studies
was obtained from Zen Bio, Inc. (Research Triangle Park, NC). The case sample blood for
pyrolytic evaluation was provided by NMS Labs (Willow Grove, PA).
4.2.2 Sample Preparation
Stock standard solutions of synthetic cannabinoids were prepared at 1 mg/ml in either
methanol (MeOH), acetonitrile (ACN) or a 50:50 mixture of MeOH-ACN dependent on
solubility and stored at -20°C. Working solutions were prepared by serial dilution at
concentrations of 10000, 1000, 100, 10, 1, 0.1 and 0.01 ng/ml. A 0.2M sodium carbonate buffer,
pH 9.4 was prepared by mixing the contents of a BupHTM carbonate-bicarbonate buffer pack to
500 ml of degassed, deionized water.
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4.2.3 Blood Extraction
To 1 ml of drug-free blood, 200 µl of working synthetic cannabinoid solution was added
to obtain the desired concentration. Five hundred microliters of 0.2M sodium-carbonate buffer,
pH 9.4, was added and vortexed for 20 s followed by the addition of 1.5 ml of 99:1 hexane-ethyl
acetate. The samples were mixed for 20 min followed by a 10 min centrifugation. The top
organic layer was transferred to a clean vial, evaporated under nitrogen gas at 40°C, reconstituted
in 200 µl of mobile phase (50:50 MeOH-ACN with 0.1% formic acid), and transferred to a
labeled autosampler vial. This protocol was adapted from methodology previously reported by
Knittel, et al30.
4.2.4 Instrumental Analysis
The chromatographic analysis for this study was carried out using a Shimadzu (Houston,
TX) prominence high performance liquid chromatograph (HPLC) coupled with an AB SCIEX
3200 QTRAP LC-MS/MS (Framingham, MA) system equipped with a Turbo VTM source. The
LC was comprised of a DGU-20A3R degasser, LC-20AD pump, SIL-20AC HT autosampler and
CTO-20AC oven. Analyst software 1.6.3 was used for data acquisition and analysis.
For chromatic separation, a Phenomenex Kinetex C18 analytical column (30 x 2.1 mm ID
x 2.6 µm) was utilized (Torrance, CA). The oven compartment was held at 40°C, and the
injection volume was 5 µl. A gradient elution program was developed with water with 0.1%
formic acid (mobile phase A) and ACN with 0.1% formic acid (mobile phase B) with a flow rate
of 0.5 ml/min. The conditions of the gradient were: starting conditions 20% B and held for 0.3
min, increased to 40% B at 2.3 min, ramped to 50% B at 12.3 min, ramped to 70% B at 14.3 min,
returned to 20% B at 15.3 min and held for 0.6 min for a total run time of 16.0 min. Baseline
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resolution was not fully achieved, but the target analytes had different transition, which allowed
for accurate compound determination.
The mass spectrometer was operated in positive mode with electrospray ionization (ESI)
and MRM acquisition. The source dependent parameters during analysis were: GS1 gas was set
at 10 psi, GS2 at 0 psi, CUR (curtain) at 10 psi, CAD (collision cell) at medium, IS (ion spray
voltage) at 5,500 V and no heat was applied to the source. Two MRM transitions were monitored
for each optimized compound. The optimized compound dependent parameters were determined
by direct-infusion analysis with a flow of 10.0 ml/min. The parameters that were optimized
included declustering potential (DP), entrance potential (EP), collision cell entrance potential
(CEP), collision energy (CE) and collision cell exit potential (CXP). The MRM transitions and
optimized parameters for each pertinent compound are listed in the supplementary material;
Appendix C. Additional compounds were optimized and monitored as possible pyrolytics, but
were omitted from Table C1 due to not being observed in the blood sample analysis.
Additionally, a standard of 4-methylcinnoline was unavailable, so the transition masses are
predicted based on the obtained product ions of cinnoline, and the compound dependent
parameters were kept the same as cinnoline due to the minor difference of a methyl group in
structure.
4.2.5 Method Validation
The goal of this study is to observe thermal degradation products in a qualitative manner,
however, a number of parameters were validated for the adapted methodology based on a
previous report and SWGTOX guidelines including linearity, limit of detection (LOD), limit of
quantitation (LOQ), within-day and between-day precision, accuracy, extraction recovery and
matrix effects. The linearity was determined by analyzing a multiple concentration calibration
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curve over 10 consecutive days. The linear relationship of the minimum six point curve was
evaluated by calculating the regression via the least squares method. The determined R2 values
were required to be 0.990 or better. The LOD and LOQ were determined based on back
calculating each sample concentration with the generated curve and comparing it to the
theoretical concentration. A level of acceptance was set at ±20%. The LOD was defined as the
lowest analyzed concentration at which the relative retention time was within 3% and produced
consistent signal intensity, while the LOQ was defined as the lowest concentration that met the
set ±20% criteria.
The instrument precision and accuracy was evaluated at low, middle and high
concentrations within the linearity range of 10, 100 and 1,000 ng/ml respectively. The within-day
precision was determined by analyzing 5 aliquots of a single extraction. The between-day was
evaluated over a 10 day period of a single aliquot. The precision acceptance value was set at a
coefficient of variance (CV) or ≤ 20%. As for the accuracy, it was defined as the percent
difference of the average calculated concentration and the theoretical fortified concentration. For
acceptance, the percent difference was required to be ≤ 20%.
Extraction recovery and matrix effects were evaluated at both a low and high
concentration within the linearity range of 50 and 500 ng/ml respectively, in triplicate. For each
examined compound concentration pair, three samples were generated. Sample 1 consisted of the
analyte of interest in the extraction solvent. Sample 2 was a pre-extraction sample produced by
fortifying reference standard into blank blood and then extracting as previously described.
Sample 3 was the post-extraction sample made by adding reference standard after extraction but
before the evaporation process. Using these samples, the extraction recovery was determined by
the sample 2 response divided by the sample 3 response. The matrix effect was defined as the
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sample 3 response divided by the sample 1 response. A value of over 100% indicates ion
enhancement, while values under 100% indicate ion suppression.
4.2.6 Blood Analysis
Case blood samples were obtained along with the identification of the parent synthetic
cannabinoids that were detected during analysis. These identifications are outlined in Table 4.1,
and the structures are shown in Figure 4.2. Each compound has an equivalent indazole core
structure except 5F-PB-22, which is indole based. Such information was used to predict the
thermal degradation products to monitor for in this project, and it is important to note that due to
similar structural make-up, they could produce common products. The volume of blood per
sample varied from approximately 1-5 ml, and each extraction analysis was carried out on 1 ml
portions via the methodology previously described. Where applicable each sample was extracted
and analyzed in triplicate, however a few samples were only able to be analyzed once.
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Table 4.1 – Previously detected synthetic cannabinoids within the case blood samples
obtained and reported from NMS Labs
Description
Sample Number
Compound
1
AB-PINACA
2, 21
AB-FUBINACA
3, 17
MAB-CHMINACA
Single Drug
4, 18, 22, 23
ADB-FUBINACA
5, 6, 7, 9, 10, 13, 16, 19
5F-ADB
8
MMB-FUBINACA
14
5F-AMB
Sample Number
Compounds
5F-ADB
11
MMB-FUBINACA
FUB-AKB-48
12
AB-CHMINACA
MAB-CHMINACA
5F-PB22
Mixtures
FUB-AKB-48
15
AB-CHMINACA
MAB-CHMINACA
5F-ADB
20
ADB-FUBINACA
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Figure 4.2 – The structure of each parent synthetic compound contained in the 23 case
blood samples

4.3 Results
4.3.1 Method Validation
Linearity was assessed using eight concentrations ranging from 0.01 – 1,000 ng/ml
comprised of 0.01, 0.1, 1, 10, 25, 50, 100 and 1,000 ng/ml standard concentrations. The 8
concentrations were necessary as the low end concentrations were not consistently observed and
at least six points were desired for the calibration curves. The linearity was found to be
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acceptable across the analyzed concentrations for each compound based on the produced
calibration curve R2 values. The LOD was commonly observed to be approximately 1 ng/ml but
as low as 0.01 ng/ml. As for the LOQ’s, they ranged from 1 – 10 ng/ml. The experimentally
obtained values for each compound are summarized in Table C2.
The within-day and between day precision and accuracy were evaluated at a low, mid and
high concentration across the linearity range, and chosen levels were 10, 100 and 1,000 ng/ml.
All within-day and between-day precisions were acceptable with the exception of the 1,000
ng/ml samples of AB-PINACA being scarcely unacceptable with CV values for between-day and
within-day of 20.5 and 20.7% respectively, and the 1,000 ng/ml between-day sample for FUBAKB-48 and 100 ng/ml within-day sample of 5F-ADB at 20.9 and 20.3 respectively. The
between-day accuracies were accepted with the exception of MMB-FUBINACA at 100 ng/ml
with a percent difference of 21.9%. The between-day accuracies all fell under 20%. The data of
all calculated precision and accuracy values are detailed in Table C3.
The extraction efficiency and matrix effects were evaluated at two concentrations, 50 and
500 ng/ml, which were a low and high concentration value within the linear ranges. The
corresponding data is within Table C4. The extraction recoveries ranged from 64.7 – 165.16 %.
The extraction protocol was taken from a previous report, which had a recovery range of 70 –
174 %30. The recoveries reported here are comparable with a slightly smaller overall range. The
matrix effects were determined to range from 41.91 – 155.71 %, which again was comparable to
the previous report as their reported range was 27 – 147 %30. The majority of the samples were
under 100%, indicating ion suppression, but when ion enhancement was observed, it was at a
much larger rate. Twelve of the 30 total samples, nearly half were within ± 20 %, showing little
matrix effects from the blood.
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4.3.2 Blood Analysis
The samples were analyzed up to three times dependent on the amount of blood supplied.
Thermal degradation products were detected in each sample except one, which may have been
due to the small volume of blood obtained or due to the user not ingesting the drug compound
via a smoking process. Six compounds were consistently observed at a signal level of greater
than three times the noise level. The results and structures of the observed pyrolytic products are
outlined in Table 4.2 and Figure 4.3. Each contained either the core indazole ring or the
expanded ring form of indazole, cinnoline, which is a process indicative of pyrolysis. From the
samples containing a single drug, 4-hydroxycinnoline, 1H-indazole-3-carboxaldehyde and
cinnoline were commonly observed, which is emblematic of each parent drug containing
structurally similar cores. The pyrolytic products observed within the mixtures are consistent
with expected results based on the analyses on the single drug samples.
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Table 4.2 – Observed thermal degradation products from the case sample blood samples.
1: 4-Hydroxycinnoline; 2: 1H-Indazole-3-carboxaldehyde; 3: Indazole; 4: Cinnoline;
5: N- Methylindazole; 6: 4-Methylcinnoline; 7: N-Pentylindazole. *- Not Confirmed
Compound
TD(s) Observed Frequency
1 and 2
6 of 8
4 and 5
4 of 8
5F-ADB
6*
3 of 8
7
1 of 8
5F-AMB
1, 2 and 4
1 of 1
Single
1 and 2
2 of 2
Drug
AB-FUBINACA
3 and 4
1 of 2
AB-PINACA
1 and 2
1 of 1
1 and 2
4 of 4
ADB-FUBINACA
4
1 of 4
MMB-FUBINACA
1, 2 and 7
1 of 1
Compounds
TD(s) Observed
5F-ADB
N/A
MMB-FUBINACA
AB-CHMINACA
FUB-AKB-48
MAB-CHMINACA

1 and 2

5F-PB-22
AB-CHMINACA
FUB-AKB-48
MAB-CHMINACA

1, 2 and 6*

5F-ADB
ADB-FUBINACA

1, 2, 4 and 5

Mixtures
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Figure 4.3 – The structure of the 7 consistently observed thermal degradation products
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4.4 Discussion
As the results of the current study began to evolve, a review of unwanted factors was
conducted. The assurance of the pyrolytics being present within the blood itself and not produced
through analysis, specifically the electrospray ion source (ESI), was confirmed as the degradants
eluted at different times than the parent compounds. If they were produced within the ESI, the
retention times would be equivalent as the ESI is applied after the chromatography. The
collection time of the blood relative to the ingestion time is unknown, so it is understood that
additional pyrolytics may have been present and already undergone metabolism. Urine analysis
would need to be carried out to fully understand the spectrum of degradants and their metabolites
that may be present for toxicological assays, along with a time course for such breakdown.
Nineteen of the 23 blood samples contained a single drug compound, and in comparing
the results within samples containing the same drug, a few patterns are apparent. Each of the 6
parent cannabinoids produced both 4-hydroxycinnoline and 1H-indazole-3-carboxaldehyde.
Cinnoline was present in samples of 4 of the 6 parent cannabinoids, which is the other
predominantly observed pyrolytic. The remaining 4 degradants seen were more sporadic and
typically in a relatively lower abundance. The greater abundance and more consistent production
of degradants 1, 2 and 4 is to be expected based on the predicted breakdown of the parent
cannabinoids. The amine bond located within the indazole ring and the amide group would be
expected to cleave as carbon-nitrogen bonds are relatively weak. This process would produce
compound 2, and then a ring expansion process of the indazole ring allows for the production of
compound 1. Lastly, the dihydroxylation of compound 1 would produce compound 4.
The data analysis of the single drug samples also provided some anomalies. There were 8
samples containing solely 5F-ADB, but two samples did not appear to produce all of the same
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degradants as the other 6. Samples 13 and 16 produced only compound 6, 4-methylcinnoline. It
is first important to note that both of these samples had a small volume of blood and were only
able to be analyzed once. The presence of compound 6 in general was interesting as it was never
observed in samples where compound 4, cinnoline, was present. These degradants differ by only
a methyl group, and as previously described, the MRM of 4-methylcinnoline was predicted
based off of the cinnoline optimized parameters. Further confirmation of 4-methylcinnoline is
necessary to definitively determine if in fact both compounds are present or just one. As for ABPINACA, 5F-AMB and MMB-FUBINACA, there was only one single drug sample, thus further
replicates of these is desired to support the observed products, but the observed thermal
degradants is understandable based on the resemblance between them and the other parent drugs
analyzed.
The thermal degradants within the mixtures appeared to coincide with those observed
within the single drug samples, with the exception of sample 11, which produced no results.
Sample 11 had less than 1 mL of blood, which may have had an effect on the lack of pyrolytic
product detection, and additionally, the user may have not smoked the drug as the route of
ingestion. Sample 12 contained AB-CHMINACA, FUB-AKB-48 and MAB-CHMINACA,
which were not amongst the single drug samples. Compounds 1 and 2 were detected and justified
as these cannabinoids differ in structure of substituent groups, not the core structure producing
such degradants. However, it cannot be confirmed which compound may have produced the
degradants or if each did individually. Sample 15 contained the most diversity of cannabinoids, 4
different compounds. As in sample 12, the degradants could be present due to any of the parent
cannabinoids incorporated in the sample except for 5F-PB-22. This is the only instance of 5FPB-22, but at this time it cannot be stated that it provided any of the current pyrolytics as it
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contains an indole base versus the indazole base presently detected. Further analysis into 5F-PB22 and other indole based cannabinoids may yield thermal degradants not observed here. The
final mixture, sample 20, contained 5F-ADB and ADB-FUBINACA, which were the two
cannabinoids analyzed as single drugs at the highest rate. Degradant compounds 1, 2, 4 and 5
were detected. Compound 5 had not been detected in the ADB-FUBINACA samples, and is
perceived to be produced by 5F-ADB, while the other 3 could be present due to either compound
or both.
It is challenging to unambiguously define what makes two compounds “similar” to one
another, but for the purposes of this discussion, the detected pyrolytics are deemed “similar” to
serotonin based on their structural base. Serotonin consists of an indole ring structure with an
alkyl amine chain and a hydroxyl group. The seven thermal degradants described here contain
either an indazole or cinnoline ring base. These differ from the serotonin indole base by only a
substitution of nitrogen for carbon in indazole or a single carbon increase in ring size. It is
plausible that these base ring structures would interact with the same receptor binding sites as
serotonin. Their presence could then be a factor in the symptoms that overlap with serotonin
syndrome.

4.5 Conclusion
The detection of various thermal degradant products in the current study demonstrates the
necessity for further research into their activity, metabolism and possible toxicity. They cannot
be dismissed as a frivolous exploration. This report coupled with previous reports clearly
establishes not only the production of pyrolytic products, but their ingestion by a user while
smoking such cannabinoids. The findings presented here also take the next step in connecting
cannabinoids to the possible toxic side effect of serotonin syndrome. It is now established that
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numerous degradants with similar core structures to serotonin are not only produced, but also are
ingested by the user. As their presence in the vapor is known, innocent bystanders may also
ingest the pyrolytic products. Further research endeavors in this area may aid in answering some
relevant issues created with synthetic cannabinoids.
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Chapter 5: Conclusions and Future Directions
5.1 Impact of Conclusions
This study has successfully identified numerous thermal degradation products for a
representative group of synthetic cannabinoids, established a predictive model for forecasting
thermal degradation products of cannabinoids not yet analyzed, validated an LC/MS/MS method
for a collection of synthetic cannabinoids and detected a number of thermal degradants within
post mortem blood samples. The current research has reiterated the lack of knowledge in the
field of drug pyrolysis, and demonstrates a strong proof of concept insight to open discussion
into the effect of thermal degradation products on the toxicological effects of synthetic
cannabinoids.
The first phase of this project developed a novel approach to mimicking a smoking
process while utilizing an exhaustive sample collection method for the pyrolysis of synthetic
cannabinoids. The results of the pyrolysis studies unveiled that a single synthetic cannabinoid
may produce up to 10 – 15 thermal degradation products. The observed predicted products
contained compounds that share core structures to previously known toxic compounds. The
pyrolytic products may produce similar toxicity to users upon inhalation as well as bystanders
whom may inhale the produced vapors.
Following the demonstration of thermal degradation product formation, to provide a
supported possibility of such products being toxic, they must first be proven to be ingested. True
case sample post mortem blood was obtained to evaluate the presence of thermal degradation
products. The set of synthetic cannabinoids present within the blood samples were previously
identified, and a new LC/MS/MS method was validated for the aforementioned cannabinoids
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after optimization of all pertinent compounds. Prior to the current study, only two thermal
degradants have been detected in toxicological specimen. This study expands the thermal
degradants detected in post mortem samples, and supports the need for continued research
investigations into the metabolism, binding activity and toxicity of set products.
Fields of forensic science including drug analysis, toxicology assays and medicolegal
investigations can profit from the results of this study. Drug paraphernalia can be analyzed for
degradant products left behind to establish a basis for the investigation as certain markers may
indicate the use of particular drug compounds. The thermal degradation products are also
markers in toxicology specimen to indicate that the mode of ingestion was smoking or
inhalation. Lastly, as effects of the thermal degradants are defined, the gained knowledge will be
impactful on medicolegal assessments.

5.2 Future Directions
As this was the first broad monitoring of pyrolytic products in post mortem blood,
additional studies for the identification of more pyrolytics should be conducted. As more
pyrolytic products are identified, the compounds can be added to monitoring assays and
evaluated for their presence as well. Post mortem samples must be continued to be evaluated for
not only the parent cannabinoids, but their pyrolytic products too. After the determination of
other pyrolytics utilizing the established methodology, a quantitation step must be developed.
As quantitation of pyrolytic products within toxicology specimen is performed, a number
of important pieces of information may be obtained. First and foremost, it will provide insight
into the types of pyrolytics that are most commonly ingested and need to be further researched.
Once the methodology is set, controlled inhalation studies may be conducted to determine a
percent breakdown of the parent cannabinoid as well as rates of ingestion. This type of research
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would need to be carried out using mice or rats, as it would be unethical to have human first start
smoking such dangerous drug compounds. The rates of ingestion could be adapted for an
estimated value in humans, and provide a number of products that should be evaluated for their
effects post ingestion.
After the thermal degradants are ingested they will have their own metabolic profile.
Metabolism studies may be carried out on the pyrolytic products that displayed the most promise
in the ingestion rates studies. The unique metabolites identified from the pyrolytics will offer
markers for the route of ingestion in urine samples to couple with the parent pyrolytic products in
blood. The parent cannabinoid compounds are not always present by the time specimen are
collected, so the additional target analytes provided by the pyrolytic products and their
metabolites vastly increase the chances of the detection of a marker indicating the use of
synthetic cannabinoids.
Once an encompassing set of target analytes is completed, it would be necessary to
evaluate their activity within the body. The products may still hold affinity to the cannabinoid
receptors, or as previously mentioned, a number of pyrolytics may have an affinity for serotonin
receptors. The overall activity of each product as well as their metabolites would need assessed
to completely understand how a user may be affected by smoking synthetic cannabinoids. Not
only is the pharmacology of the products crucial, but also their possible toxicity. Toxicity studies
should be performed to evaluate if their presence may be one of the causes of the additional
toxicity observed with synthetic cannabinoids outside of the common tetrad. There is valuable
information to be gained from further investigation into the pyrolysis of synthetic cannabinoids
and their thermal degradation products. They cannot simply be dismissed as a non-factor at this
point with fully evaluating all of these possibilities in future research endeavors.
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A copy of the permissions agreement from the Journal of Analytical Toxicology
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Appendix B
Supplementary Material for Chapter 2: Qualitative Analysis and Detection of the Pyrolytic
Products of JWH-018 and 11 Additional Synthetic Cannabinoids in the Presence of
Common Herbal Smoking Substrates

Figure B1 – Photograph of the in-house built apparatus
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Figure B2 – Schematic of the quartz tubing T-junction where the pyrolysis was contained
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Figure B3 – Schematic of the bored Teflon plug used to hold the pyrolysis apparatus parts and
seal system

Figure B4 – The heating signature data of the propane torch with no herbal material present
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Figure B5 – Heating signature of the reaction zone with each herbal material present, and the
average of all trials indicated by the black dashed line
The first step was to show that the heating signature produced by the propane torch was
consistent between trials. Evaluation was carried out by placing the end of the torch
approximately 2 ½” from the T-junction, so that the tip of the inner blue cone of the flame was in
direct contact with the quartz tube at the reaction zone. This was first carried out with no plant
material present to allow for observation of the reproducibility of the heating process, and the
temperature was monitored for 40 seconds in 10 replicate trials. The next step was to add the
herbal material to ensure burning commenced and that a “smoking-like environment” could be
established. Twelve pyrolysis trials of the six herbal substrates were performed with a burning
time of 40 seconds and an n=2 for each species, and the heat signature was monitored.
The propane torch produced a consistent heat signature as the heat was able to spread uniformly
throughout the reaction zone. However, the independent herbal matrix pyrolysis trials displayed
variability. This is due to the dependency on when and how that herbal material ignites and
burns. The difference between these could be attributed to several hypothesized factors. The first
is the dependency on where the plant material ignites and how the burning spreads. The
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thermocouple is centered in the reaction zone, but it is challenging to control the ignition and
spread across the plant. Thus the proximity to the thermocouple may produce variability in the
temperature reading between trials. Another possible factor is leaf size and density of the herbal
substrate, which may cause a difference in actual amount of herbal material present as only the
mass was held constant. Finally, different heat capacities may contribute as well, but these values
are unknown.

Table B1 – Proposed identification of products observed in herbal material pyrolysis
Herbal Material Pyrolytics Identification
Phenol
4-Methylphenol (p-Cresol)
4-Hydroxypyridine (4-Pyridinol)
1,2-Benzenediol (Catechol)
2,3-dihydro-Benzofuran
1,2-Benzenediol (Hydroquinone)
2-methoxy-4-vinyl-Phenol
1,2-anhydro-β-D-Glucose
(Z)-9-Octadecenenitrile (Oleanitrile)
(Z)-9-Octadecenamide (Oleamide)

Each of the six herbal species was pyrolyzed in triplicate. If a chromatographic peak was
observed within +/- 0.05 min, it was deemed to be consistently produced. Ten chromatographic
peaks were observed and tentatively identified. The tentative identifications of these ten products
are shown in the table below. The products observed were consistent with previous plant matter
pyrolysis studies. These studies have been conducted on different plant species, but display
precedence of the varieties of compounds expected through the pyrolysis of plant material. In the
1970’s, it was reported that plant pyrolysis produces a myriad of phenol and methoxyphenol type
compounds and a study by Boon et al reported a major product of the Scirpus species to be 4vinyl-phenol, supporting reports of phenol-like pyrolytic products1-4. Cellulose is a large part of
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plant structure and degrades into several compounds, but one in specific is 1,6-anhydroglucose,
which further breaks down into furan-like compounds5-6. Recent studies support furan-like
product findings such as a 2005 study on tobacco pyrolysis, where the presence of phenol,
pyridine, cresol, benzofuran, and dihydrobenzofuran were reported7. Two products observed in
this paper, oleanitrile and oleamide, initially seemed surprising, but two recent studies show
otherwise. Heo et al have shown that oleamide is present in many plant species, one specifically
Ziziphus jujuba, and just this year, Jin et al shows that oleanitrile is present in at least the plant
species of Dendrobium officinale and Dendrobium huoshanense8-9.

Figure B6 – Schematic of the exhaustive sampling of JWH-018 on Damiana to optimize the
number of washes and replicates
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Appendix C
Supporting data and side project conducted, but not included in the chapter 2 manuscript.

Percent Recovery Study of Pyrolysis Methodology:
The samples for pyrolysis on the herbal matrices were prepared by spraying the drug
compound solution onto the matrix before allowing the solvent to evaporate to leave the drug
behind. To evaluate the percent recovery, it was necessary to take the process step by step to
determine any observed loss. As this project would eventually reach pyrolysis recovery, caffeine
was chosen for this study because of its thermal stability. At this stage, breakdown was undesired
to allow for quantitation of a single signal. Caffeine-d3 was used as an internal standard for
quantitation. Establishing a known amount of drug sprayed onto sample was essential, and the
first step was to determine the volume of solution dispensed per spray to allow for accurate
concentration control.
This was examined by two methods. Both methods utilized the monitoring of weight
difference to equate to volume using the density of water. Method 1 was to take the average
weight difference of 10 sprays with 10 replicates. The data for this method is shown below in
Table C1. Method 2 was to find the mass difference of each spray over the span of 25 sprays.
The number of sprays was plotted vs the volume added, and the best fit line was found. The
slope of this line is observed as the volume added per spray. The data and plot for method 2 are
shown in Table C2 and Figure C1. Method 1 gave a volume per spray of 0.0421 ±0.00139 ml,
and method 2 produced a volume of 0.0403 ml, which is slightly outside the range of method 1
by 0.00041 ml. For the remainder of the study, the Method 1 volume was used.
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Table C1 – Data for method 1 of the determination of volume per spray of the sprayer used for
sample preparation. * : Density of water used was 0.9982 g/ml due to a 20°C environment
Initial Mass (g) Final Mass (g) Mass H2O Added (g) Volume H2O Added (mL)*
10.07509
10.46708
0.39199
0.3927
10.46708
10.89499
0.42791
0.4287
11.05308
11.50102
0.44794
0.4487
11.50102
11.92302
0.422
0.4228
11.92302
12.33440
0.41138
0.4121
12.33440
12.75682
0.42242
0.4232
12.75682
13.17491
0.41809
0.4188
13.17491
13.59617
0.42126
0.4220
13.59617
14.01287
0.4167
0.4175
14.01287
14.43478
0.42191
0.4227
Avg. Vol. of 10
sprays =
Std. Dev. =
Avg. Vol. per spray =
Std. Dev. Per spray =

0.4209
0.0139
0.0421
0.00139

98

Table C2 – The mass data for method 2 of the determination of the volume per spray.
Number of
Mass of
Total H2O Mass
Total Volume H2O
Sprays
Vial (g)
Added (g)
Added (mL)*
0
14.43204
0
0
1
14.47436
0.04232
0.0424
2
14.51576
0.08372
0.0839
3
14.55515
0.12311
0.1233
4
14.59753
0.16549
0.1658
5
14.63892
0.20688
0.2073
6
14.67970
0.24766
0.2481
7
14.72175
0.28971
0.2902
8
14.76194
0.3299
0.3305
9
14.80091
0.36887
0.3695
10
14.84014
0.4081
0.4088
11
14.88021
0.44817
0.4490
12
14.91791
0.48587
0.4867
13
14.95873
0.52669
0.5276
14
14.99902
0.56698
0.5680
15
15.03883
0.60679
0.6079
16
15.07958
0.64754
0.6487
17
15.12238
0.69034
0.6916
18
15.16474
0.7327
0.7340
19
15.20188
0.76984
0.7712
20
15.24196
0.80992
0.8114
21
15.28286
0.85082
0.8524
22
15.32499
0.89295
0.8946
23
15.36353
0.93149
0.9332
24
15.40079
0.96875
0.9705
25
15.44315
1.01111
1.0129
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Figure C1 – Plot of volume added vs number of sprays with the equation of best fit line showing
the volume per spray as the slope

The next step was to determine the mass of drug that reaches the herbal matrix. In the
process of spraying the drug solution onto the matrix, two variables can lead to the loss of drug.
One is due to the evaporation itself, and the second is to possible loss due to not actually being
sprayed onto the herbal mixture. The spray is a mist, so solution could be left behind on weigh
boat containing the matrix. The loss of drug for each step was evaluated to establish a drug
concentration to be on the herbal matrix for pyrolysis after the sample preparation step.
First was the evaporation alone. This was carried out by removing the variable of the
spreading mist by spraying the solution directly into a vial. The collected solution was allowed to
evaporate, reconstituted, spiked with an internal standard and analyzed via GC/MS. The data for
this step of the study is shown in Table C3. Sample calculations are shown below the table for
SV1. The mean percent recovery of 69.5 will be used in following steps to calculate the amount
of drug that should reach the herbal matrix, not barring loss due to mist spreading or being left
behind on the weigh boat during sample preparation.
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Table C3 – Data for determining the loss of drug compound due to evaporation only.
Sample
Number
SV1
SV2
SV3
SV4
SV5
SV6
SV7
SV8
SV9
SV10
SV11

Mass
Caffeine (mg)
20.0
20.0
20.1
19.9
19.9
19.9
19.9
20.1
20.1
20.1
20.0

Reconstitution Recoverd
Vol. (mL)
Mass (mg)

Percent
Recovery

Analyzed
Vol. (mL)

4
16.5
4
12.8
4
12.1
4
12.2
4
12.5
4
13.4
4
14.5
4
13.5
4
15.0
4
14.5
4
15.8
Mean =
13.9
Std. Dev. =
1.5
Range = 12.4 - 15.4

82.3
64.2
60.2
61.4
63.1
67.5
73.0
67.4
74.5
72.1
78.9
69.5
7.2
62.3 - 76.7

1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
Mean =
Std. Dev. =
Range =

Mass Sample
Mass Std. Std. Peak
Sample Area
Analyzed (mg)
Analyzed (mg)
Area
6.17
4.81
4.54
4.58
4.71
5.04
5.45
5.08
5.62
5.43
5.91
5.21
0.55
4.66 - 5.76

530783232
580927552
517711232
452271360
423705344
432123520
475603680
414302976
434313696
428123840
408213984

0.400
0.400
0.400
0.400
0.400
0.400
0.400
0.400
0.400
0.400
0.400

34403080
48270736
45623784
39483664
36016228
34295264
34917392
32622774
30929504
31511178
27609438

𝑀𝑎𝑠𝑠 𝑆𝑡𝑑. 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
) 𝑋 (𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑟𝑒𝑎)
𝑆𝑡𝑑. 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎

𝑀𝑎𝑠𝑠 𝑆𝑉1 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (

0.400 𝑚𝑔
) 𝑋 (53078232) = 6.17 𝑚𝑔
34403080

𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠 = (
) 𝑋 𝑅𝑒𝑐𝑜𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑖𝑜𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 𝑉𝑜𝑙𝑢𝑚𝑒

6.17 𝑚𝑔
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑆𝑉1 𝑀𝑎𝑠𝑠 = (
) 𝑋 4 𝑚𝑙 = 16.5 𝑚𝑔
1.5 𝑚𝑙

𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (

𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
) 𝑋 100%
𝐶𝑎𝑓𝑓𝑒𝑖𝑛𝑒 𝑀𝑎𝑠𝑠

𝑆𝑉1 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (

16.5 𝑚𝑔
) 𝑋 100% = 82.3%
20.0 𝑚𝑔

Next step was to determine the average amount of drug lost during the sample
preparation step of spraying the herbal matrix. This could be done in two ways: 1) spray smaller
volumes in multiple cycles to more precisely spray onto the matrix and allow evaporation in
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between each 2) spray the full volume at once and allow for one evaporation step. After the drug
was displaced onto the herbal matrix and dried, it was soaked in fresh solvent, spiked with
internal standard and analyzed via GC/MS. For the calculations, the percent recovery was based
off of the possible 100% being 69.5% of the total mass due to the evaporation loss from the
previous step. The data for both applications are shown below in Table C4 and Table C5, and a
sample calculation of P-SP1 and P-SA1 are shown below. It was observed that the technique of
spraying the entire drug solution volume onto the herbal matrix at once left a higher amount of
drug on the matrix at a mean of 75.7%.

Table C4 – Data for the determination of loss due to the spraying of drug solution onto the herbal
matrix by periodic sprays
Sample
Mass
Mass
Number Caffeine (mg) Delivered (mg)
P-SP1
P-SP2
P-SP3
P-SP4
P-SP5
P-SP6
P-SP7
P-SP8
P-SP9
P-SP10

20.0
19.9
19.9
20.0
20.0
20.1
19.9
20.0
20.1
19.9

13.9
13.8
13.8
13.9
13.9
14.0
13.8
13.9
14.0
13.8

Delivered Mass = Caffeine Mass x 69.5%

Reconstitution Recoverd
Vol. (mL)
Mass (mg)

Percent
Recovery

Analyzed Sample Mass
Mass Std. Std. Peak
Sample Area
Vol. (mL) Analyzed (mg)
Analyzed (mg)
Area

6
8.73
62.8
1.5
6
6.97
50.4
1.5
6
6.54
47.3
1.5
6
7.16
51.5
1.5
6
7.80
56.1
1.5
6
8.09
57.9
1.5
6
7.17
51.8
1.5
6
8.07
58.1
1.5
6
8.30
59.4
1.5
6
7.79
56.3
1.5
Mean =
7.66
55.2
Mean =
Std. Dev. =
0.68
4.8
Std. Dev. =
Range = 6.98 - 8.34 47.3 - 62.8 Range =

2.18
1.74
1.63
1.79
1.95
2.02
1.79
2.02
2.07
1.95
1.92
0.17
1.75 - 2.09

160872448
146505280
130672840
132992016
137002128
139769264
130919344
137043904
131053472
132081552

0.400
0.400
0.400
0.400
0.400
0.400
0.400
0.400
0.400
0.400

29477514
33609992
31980474
29715754
28112380
27630382
29215846
27173758
25266474
27121258

𝑀𝑎𝑠𝑠 𝑆𝑡𝑑. 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
) 𝑋 (𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑟𝑒𝑎)
𝑆𝑡𝑑. 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
0.400 𝑚𝑔
𝑀𝑎𝑠𝑠 𝑃 − 𝑆𝑃1 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
) 𝑋 (160872448) = 2.18 𝑚𝑔
29477514
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠 = (
) 𝑋 𝑅𝑒𝑐𝑜𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑖𝑜𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 𝑉𝑜𝑙𝑢𝑚𝑒
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𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑃 − 𝑆𝑃1 𝑀𝑎𝑠𝑠 = (

𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (

2.18 𝑚𝑔
) 𝑋 6 𝑚𝑙 = 8.73 𝑚𝑔
1.5 𝑚𝑙

𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
) 𝑋 100%
𝐷𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠

8.73 𝑚𝑔
𝑃 − 𝑆𝑃1 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (
) 𝑋 100% = 62.8%
13.9 𝑚𝑔

Table C5 – Data for the determination of loss due to the spraying of drug solution onto the herbal
matrix all at once
Sample
Mass
Delivered
Number Caffeine (mg) Mass (mg)
P-SA1
P-SA2
P-SA3
P-SA4
P-SA5
P-SA6
P-SA7
P-SA8
P-SA9
P-SA10

20.1
20.0
20.1
20.0
20.0
20.1
20.1
19.9
20.1
20.0

14.0
13.9
14.0
13.9
13.9
14.0
14.0
13.8
14.0
13.9

Delivered Mass = Caffeine Mass x 69.5%

Reconstitution Recoverd
Vol. (mL)
Mass (mg)
6
6
6
6
6
6
6
6
6
6
Mean =
Std. Dev. =
Range =

9.80
10.16
10.01
10.17
8.68
9.91
13.81
11.45
11.36
10.12
10.5
1.4
9.1 - 11.9

Percent
Recovery

Analyzed
Vol. (mL)

70.1
1.5
73.1
1.5
71.6
1.5
73.2
1.5
62.4
1.5
70.9
1.5
98.9
1.5
82.8
1.5
81.3
1.5
72.8
1.5
75.7
Mean =
9.9
Std. Dev. =
62.4 - 98.9
Range =

Sample Mass
Mass Std. Std. Peak
Sample Area
Analyzed (mg)
Analyzed (mg) Area
2.45
2.54
2.50
2.54
2.17
2.48
3.45
2.86
2.84
2.53
2.64
0.35
2.29 - 2.99

177612592
176853472
180016800
189699520
181174656
175969472
192910896
171856880
170186608
172357584

0.400
0.400
0.400
0.400
0.400
0.400
0.400
0.400
0.400
0.400

29001432
27857740
28779008
29833854
33405652
28413448
22345990
24013084
23964374
27248658

𝑀𝑎𝑠𝑠 𝑆𝑡𝑑. 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
) 𝑋 (𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑟𝑒𝑎)
𝑆𝑡𝑑. 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
0.400 𝑚𝑔
𝑀𝑎𝑠𝑠 𝑃 − 𝑆𝐴1 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
) 𝑋 (177612592) = 2.45 𝑚𝑔
29001432
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠 = (
) 𝑋 𝑅𝑒𝑐𝑜𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑖𝑜𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 𝑉𝑜𝑙𝑢𝑚𝑒

𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑃 − 𝑆𝐴1 𝑀𝑎𝑠𝑠 = (

2.45 𝑚𝑔
) 𝑋 6 𝑚𝑙 = 9.80 𝑚𝑔
1.5 𝑚𝑙
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𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (

𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
) 𝑋 100%
𝐷𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠

𝑃 − 𝑆𝐴1 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (

9.80 𝑚𝑔
) 𝑋 100% = 70.1%
14.0 𝑚𝑔

Lastly, the prepared samples were pyrolyzed to determine the recovery of the burning
methodology. The calculations were based on the assumptions of the previous two steps; 69.5%
retention from evaporation and 75.7% of that retention onto the herbal matrix. Samples were
prepped using the full volume at once technique, and the recovery was evaluated. After a burning
trial, each collected sample (quartz, tube and flask) was quantified and added together for a total
collection of drug. The data is presented within Table C6, and a sample calculation is below.

Table C6 – Data for the determination of recovery of overall sample preparation, pyrolysis and
sample collection process
Trial
Mass
Delivered
Number Caffeine (mg) Mass (mg)

Collected Reconstitution Recoverd
Analyzed
Percent Recovery
Sample
Vol. (mL)
Mass (mg)
Vol. (mL)

1

20.0

10.52

QW1
T1
F1

2

20.1

10.57

QW2
T2
F2

3

19.9

10.47

QW3
T3
F3

4

20.1

10.57

QW4
T4
F4

5

19.9

10.47

QW5
T5
F5

Delivered Mass = Caffeine Mass x 69.5% x 75.7%

1
3
3
Total =
1
3
3
Total =
1
3
3
Total =
1
3
3
Total =
1
3
3
Total =
Average =

0.00308
1.15
1.53
2.68
0.0217
1.80
2.67
4.49
0.226
1.90
4.40
6.53
0.140
1.34
3.21
4.70
0.291
1.48
4.65
6.41

0.0293
10.9
14.5
25.5
0.205
17.0
25.3
42.5
2.16
18.1
42.0
62.3
1.32
12.7
30.4
44.4
2.8
14.1
44.4
61.3

4.96

47.20

Sample Mass
Mass Std.
Std. Peak
Sample Area
Analyzed (mg)
Analyzed (mg)
Area

0.3
1.5
1.5

0.000925
0.575961
0.763497

19049
2414587
3111577

0.100
0.400
0.400

2059023
1676910
1630171

0.3
1.5
1.5

0.00651
0.90068
1.33561

159126
4212331
6200113

0.100
0.400
0.400

2444907
1870735
1856858

0.3
1.5
1.5

0.0678
0.9495
2.2003

1614094
5359954
13377304

0.100
0.400
0.400

2381402
2258061
2431886

0.3
1.5
1.5

0.0419
0.6719
1.6070

1097624
3866208
9269358

0.100
0.400
0.400

2620995
2301586
2307316

0.3
1.5
1.5

0.0872
0.7392
2.3229

2119155
4573155
15288100

0.100
0.400
0.400

2429536
2474586
2632636

𝑀𝑎𝑠𝑠 𝑆𝑡𝑑. 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
) 𝑋 (𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑟𝑒𝑎)
𝑆𝑡𝑑. 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
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0.100 𝑚𝑔
𝑀𝑎𝑠𝑠 𝑄𝑊3 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
) 𝑋 (159126) = 0.0678 𝑚𝑔
2381402

𝑀𝑎𝑠𝑠 𝑇3 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (

0.400 𝑚𝑔
) 𝑋 (5359954) = 0.950 𝑚𝑔
2258061

𝑀𝑎𝑠𝑠 𝐹3 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (

0.400 𝑚𝑔
) 𝑋 (13377304) = 2.20 𝑚𝑔
2431886

𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠 = (
) 𝑋 𝑅𝑒𝑐𝑜𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑖𝑜𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 𝑉𝑜𝑙𝑢𝑚𝑒

𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑄𝑊3 𝑀𝑎𝑠𝑠 = (

0.0678 𝑚𝑔
) 𝑋 1 𝑚𝑙 = 0.226 𝑚𝑔
0.3 𝑚𝑙

𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑇3 𝑀𝑎𝑠𝑠 = (

0.950 𝑚𝑔
) 𝑋 1 𝑚𝑙 = 1.90 𝑚𝑔
1.5 𝑚𝑙

2.20 𝑚𝑔
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝐹3 𝑀𝑎𝑠𝑠 = (
) 𝑋 1 𝑚𝑙 = 4.40 𝑚𝑔
1.5 𝑚𝑙
𝑇𝑜𝑡𝑎𝑙 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (
) 𝑋 100%
𝐷𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
6.53 𝑚𝑔
𝑆𝑎𝑚𝑝𝑙𝑒 1 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (
) 𝑋 100% = 62.3%
10.47 𝑚𝑔
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Proposed Mechanisms of the three major breakdown trends observed:

The chemistry that takes place within the pyrolytic environment is difficult to fully
understand. It has long been thought that at extreme temperatures the reactions proceed through
radical reactions, especially the ring expansion process1-3. However, this has not been proven
through the use of labelled carbon or deuterium studies. For this to occur, the compounds
involved in the reaction would be forced to initiate the production of a free radical instead of
more energy favorable electron pushing chemistry while holding true to neutral compounds4.
The common radical hypothesized to be produced is a hydrogen radical, which can take
approximately 52 kcal/mol to produce 5, where hydride shifts are typically closer to 10 kcal/mol
depending on the state of the carbocation6.The mechanism of pyrolytic breakdown on illicit
drugs is an area largely lacking in experimental data and research. For the current research, the
proposed mechanisms take the approach of simple electron pushing and hydride shifts as an
explanation for the three observed trends. This is based on this type of chemical reactions being
more energy favorable in lieu of producing free radicals. It is not to say that free radicals could
not be produced and additional mechanism are possible, especially in the extremely high
temperatures, however, it is hypothesized that these such processes would occur before such
extreme temperatures would be reached.
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Figure C2 – Proposed mechanism of a pyrolytic cleavage at the nitrogen within the indole ring
(or could be an indazole).
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Figure C3 – Proposed mechanism of a pyrolytic cleavage of the central carbonyl group on the
non-indole/indazole side.
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Figure C4 – Proposed mechanism of a pyrolytic cleavage of the central carbonyl group on the
indole/indazole side.

Figure C5 – Proposed mechanism of a ring expansion from indazole to cinnoline
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Parent Synthetic Cannabinoid to its Proposed Pyrolytic Products Breakdowns:

Figure C7 – Thermal degradation breakdown of AB-CHMINACA to its proposed observed
pyrolytic products
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Figure C8 – Thermal degradation breakdown of AB-FUBINACA to its proposed observed
pyrolytic products
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Figure C9 – Thermal degradation breakdown of AB-PINACA to its proposed observed pyrolytic
products
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Figure C10 – Thermal degradation breakdown of AM-694 to its proposed observed pyrolytic
products
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Figure C11 – Thermal degradation breakdown of AM-2201 to its proposed observed pyrolytic
products
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Figure C12 – Thermal degradation breakdown of JWH-018 to its proposed observed pyrolytic
products
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Figure C13 – Thermal degradation breakdown of JWH-073 to its proposed observed pyrolytic
products
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Figure C14 – Thermal degradation breakdown of JWH-081 to its proposed observed pyrolytic
products

117

Figure C15 – Thermal degradation breakdown of JWH-210 to its proposed observed pyrolytic
products
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Figure C16 – Thermal degradation breakdown of MAM-2201 to its proposed observed pyrolytic
products
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Figure C17 – Thermal degradation breakdown of UR-144 to its proposed observed pyrolytic
products
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Figure C18 – Thermal degradation breakdown of XLR-11 to its proposed observed pyrolytic
products

121

Shared Proposed Pyrolytic Products from Parent Synthetic Cannabinoid Breakdowns:

Figure C19 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of (1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)-Methanone
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Figure C20 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of 1H-Indazole-3-carboxaldehyde

123

Figure C21 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of 1-Methylindazole
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Figure C22 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of 1-Methylindazole-3-formamide
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Figure C23 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of 1-pentyl-3-Acetylindole
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Figure C24 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of 1-Pentylindole
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Figure C25 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of 1-Pentylindole-3-carboxaldehyde
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Figure C26 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of 1-Pentylisatin
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Figure C27 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of 3-Naphthoylindole
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Figure C28 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of 4-Hydroxycinnoline or 4-Cinnolinamine
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Figure C29 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of Formylvaline amide
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Figure C30 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of Hydroxyquinoline
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Figure C31 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of Indole
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Figure C32 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of JWH-018
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Figure C33 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of Methylindole
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Figure C34 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of N-(2-methylpropyl)-4-Cinnolinamine
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Figure C35 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of Naphthalene
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Figure C36 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of N-methyl-3-Naphthoylindole
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Figure C37 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of N-phenyl-1-Naphthamide
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Figure C38 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal
degradant of Quinoline
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Appendix D
Supplementary Material for Chapter 4: Simultaneous LC/MS/MS Monitoring of Synthetic
Cannabinoids and Thermal Degradation Products in Postmortem Blood Samples

Table D1 – Compound dependent parameters for the synthetic cannabinoids and observed
pyrolytic products. * - predicted transition ions and parameters kept the same as cinnoline as the
compounds differ by a single methyl group and a reference standard was unavailable
Compound
Synthetic Cannabinoids
5F-ADB

5F-AMB

5F-PB-22

AB-CHMINACA

AB-FUBINACA

AB-PINACA

ADB-FUBINACA

FUB-AKB-48

MAB-CHMINACA

MMB-FUBINACA

MRM
Transition (m/z)

Compound Dependent Parameters (V)
DP

EP

CEP

CE

CXP

378.2/233.1

77

6

37

30

4

378.1/213.2

74

9

27

42

3

364.3/233.1

85

5

33

30

4

364.3/213.2

85

5

24

36

4

377.4/232.3

60

5

45

31

6

377.4/144.2

65

5

20

60

3

357.5/241.2

80

10

37

40

4

357.5/144.9

90

10

15

55

3

369.4/253.2

65

6

35

30

4

369.4/109.2

65

8

23

70

4

331.5/215.3

75

5

36

32

8

331.5/145.3

75

5

12

50

3

383.5/252.9

90

5

33

32

9

383.5/108.8

95

4

24

60

3

404.5/135.1

100

10

15

27

3

404.5/107.1

95

10

20

65

3

371.3/241.3

95

5

14

37

4

371.3/145.1

95

5

20

55

5

384.4/253.1

85

6

36

31

9

384.4/225.1

85

6

26

43

4
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Pyrolytic Products
1-Methylindazole

4-Hydroxycinnoline

Indazole-3carboxaldehyde

1-Pentylindazole

Indazole

4-Methylcinnoline*

Cinnoline

133.2/117.9

58

9

11

32

3

133.2/91.2

60

7

31

42

3

147.3/92.1

67

11

12

29

2

147.3/75.2

70

10

47

51

3

147.3/117.8

50

8

13

38

3

147.3/91.8

55

8

11

26

3

189.2/133.5

40

4

20

22

4

189.2/119.2

40

4

15

35

3

119.3/92.0

52

11

11

30

3

119.3/65.8

53

11

11

45

2

144.2/102.2

80

10

13

34

4

144.2/77.0

80

10

12

37

3

130.7/102.2

80

10

13

34

4

130.7/77.0

80

10

12

37

3

Table D2 – Linearity, LOD, and LOQ values determined for each synthetic cannabinoid
Compound
5F-ADB
5F-AMB
5F-PB-22
AB-CHMINACA
AB-FUBINACA
AB-PINACA
ADB-FUBINACA
FUB-AKB-48
MAB-CHMINACA
MMB-FUBINACA

Linearity Range
(ng/ml)
1.0 - 1,000.0
1.0 - 1,000.0
0.1 - 1,000.0
1.0 - 1,000.0
1.0 - 1,000.0
1.0 - 1,000.0
1.0 - 1,000.0
1.0 - 1,000.0
1.0 - 1,000.0
1.0 - 1,000.0

LOD (ng/ml)

LOQ (ng/ml)

0.1 ≥ x ≤ 1.0
1.0 ≥ x ≤ 10.0
0.01 ≥ x ≤ 0.1
0.1 ≥ x ≤ 1.0
0.1 ≥ x ≤ 1.0
0.1 ≥ x ≤ 1.0
0.1 ≥ x ≤ 1.0
1.0 ≥ x ≤ 10.0
0.1 ≥ x ≤ 1.0
1.0 ≥ x ≤ 10.0

10.0
10.0
1.0
10.0
10.0
10.0
10.0
10.0
10.0
10.0
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Table D3 – Precision and accuracy data for both within-day and between-day evaluations
Accuracy (avg. % difference, ±%CV of x̅)

Precision (%CV)
Parent Compound

Within-day; n=5

Between-day; n=10

Within-day; n=5

Between-day; n=10

Low

Mid

High

Low

Mid

High

Low

Mid

High

Low

Mid

High

5F-ADB

1.7

7.0

20.3

1.6

7.6

18.2

11.9

11.4

10.1

17.4

11.4

0.3

5F-AMB

0.9

6.4

6.7

1.2

6.8

18.8

15.9

10.9

0.0

4.4

7.4

2.5

5F-PB-22

8.8

9.7

17.3

8.9

8.6

12.5

3.8

1.6

6.2

2.7

0.6

0.0

AB-CHMINACA

5.6

8.4

10.3

7.9

9.3

9.2

1.4

1.9

4.7

12.0

0.5

0.1

AB-FUBINACA

6.5

8.5

19.4

6.7

9.0

15.3

0.5

2.4

4.5

9.2

0.9

0.4

AB-PINACA

13.4

19.5

20.7

14.2

11.9

20.5

15.7

13.5

14.8

0.5

0.0

0.0

ADB-FUBINACA

0.9

3.1

10.3

0.8

3.6

18.8

14.4

7.4

19.0

4.2

4.8

0.0

FUB-AKB-48

8.4

16.5

17.1

8.3

16.3

20.9

17.0

4.6

4.1

4.2

3.4

1.5

MAB-CHMINACA

7.3

10.9

13.3

14.6

11.0

18.3

1.7

18.2

6.2

17.8

17.5

1.5

MMB-FUBINACA

0.5

6.1

9.7

0.9

9.2

18.6

3.1

13.6

5.7

5.6

21.9

0.4

Table D4 – Average extraction recoveries and matrix effects; analyzed at n = 3
Parent Compound
5F-ADB
5F-AMB
5F-PB-22
AB-CHMINACA
AB-FUBINACA
AB-PINACA
ADB-FUBINACA
FUB-AKB-48
MAB-CHMINACA
MMB-FUBINACA

Matrix Effect
50 ng/ml 500 ng/ml
76.9
67.9
112.3
59.8
41.9
98.3
81.8
155.7
97.1
79.6
85.1
80.5
136.1
92.3
85.4
80.8
105.2
113.2
139.6
84.2

Recovery
50 ng/ml 500 ng/ml
97.4
86.4
70.2
77.6
136.2
130.0
78.8
165.2
86.5
64.7
141.9
73.4
129.6
131.8
76.7
65.5
105.7
119.0
89.9
67.3
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Appendix E
Supporting data that was not included in the manuscript for chapter 4.
Predicted pyrolytic products of the synthetic cannabinoids present in the obtained case blood
samples:

Figure E1 – Possible thermal degradation products for the parent synthetic cannabinoid, 5F-ADB
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Figure E2 – Possible thermal degradation products for the parent synthetic cannabinoid,
5F-AMB
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Figure E3 – Possible thermal degradation products for the parent synthetic cannabinoid,
5F-PB-22
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Figure E4 – Possible thermal degradation products for the parent synthetic cannabinoid, ABCHMINACA
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Figure E5 – Possible thermal degradation products for the parent synthetic cannabinoid, ABFUBINACA
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Figure E6 – Possible thermal degradation products for the parent synthetic cannabinoid,
AB-PINACA
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Figure E7 – Possible thermal degradation products for the parent synthetic cannabinoid,
ADB-CHMINACA (MAB-CHMINACA)

151

Figure E8 – Possible thermal degradation products for the parent synthetic cannabinoid,
ADB-FUBINACA
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Figure E9 – Possible thermal degradation products for the parent synthetic cannabinoid,
FUB-AKB-48
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Figure E10 – Possible thermal degradation products for the parent synthetic cannabinoid,
MMB-FUBINACA
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Method validation linearity graphs and example chromatographs:

5F-ADB
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Figure E11 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for 5F-ADB

5F-AMB
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Figure E12 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for 5F-AMB
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5F-PB-22
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Figure E13 – Linearity plot of concentration (0.1 – 100 ng/ml) vs intensity for 5F-PB-22

AB-CHMINACA
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Figure E14 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for AB-CHMINACA
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AB-FUBINACA
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Figure E15 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for AB-FUBINACA

AB-PINACA
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Figure E16 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for AB-PINACA
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ADB-FUBINACA
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Figure E17 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for ADB-FUBINACA

FUB-AKB-48
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Figure E18 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for FUB-AKB-48
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MAB-CHMINACA
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Figure E19 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for MAB-CHMINACA
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Figure E20 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for MMB-FUBINACA
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LC chromatograms of the parent method and examples of a few blood samples:

Figure E21 – LC chromatograph of a mixture of all 10 synthetic cannabinoids

Figure E22 – LC chromatogram of a standard of 4-Hydroxycinnoline

Figure E23 – LC chromatogram of a standard of 1H-Indazole-3-carboxaldehyde
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Figure E24 – LC chromatogram of a standard of Cinnoline

Figure E25 – LC chromatogram of a standard of 1-Methylindazole

Figure E26 – LC chromatogram of a standard of Indazole
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Figure E27 – LC chromatogram of a standard of 1-Pentylindazole

Figure E28 – Example LC chromatogram of a blood sample containing indazole
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Figure E29 – Example LC Chromatogram of a blood sample containing 1-pentylindazole

Figure E30 – Example LC Chromatogram of a blood sample containing 4-methylcinnoline
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